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The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group 
of disorders involving severe, systemic, small-vessel vasculitis and are characterized by the 
development of autoantibodies against the neutrophil proteins leukocyte proteinase 3 (PR3-
ANCA) or myeloperoxidase (MPO-ANCA). The three AAV subgroups, namely granulomatosis 
with polyangiitis (GPA), microscopic polyangiitis and eosinophilic GPA (EGPA), are defined on 
the basis of clinical features. However, genetic and other clinical findings suggest that these 
clinical syndromes may be better classified as PR3-positive AAV (PR3-AAV), MPO-positive 
AAV (MPO-AAV) and, for EGPA, by the presence or absence of ANCA (ANCA+ or ANCA–, 
respectively). Although any tissue can be involved in AAV, the upper and lower respiratory tract 
and kidneys are most commonly and severely affected. AAVs have a complex and unique 
pathogenesis, with evidence for a loss of tolerance to neutrophil proteins, which leads to ANCA-
mediated neutrophil activation, recruitment and injury, with effector T cells also involved. 
Without therapy, prognosis is poor, but treatments, typically immunosuppressants, have 
improved survival, albeit with considerable morbidity from glucocorticoids and other 
immunosuppressive medications. Current challenges include improving measures of disease 
activity and risk of relapse, uncertainty about optimal therapy duration and a need for targeted 
therapies with fewer adverse effects. Meeting these challenges requires a more detailed 
knowledge of the fundamental biology of AAV, and co-operative international research and 






 The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) 
are diseases characterized by inflammation of blood vessels, endothelial injury and tissue 
damage. Three types of small-vessel vasculitis, namely granulomatosis with polyangiitis 
(GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis 
(EGPA; previously known as Churg–Strauss syndrome), feature a loss of tolerance to 
neutrophil primary granule proteins, most often leukocyte proteinase 3 (PR3; also known as 
myeloblastin) or myeloperoxidase (MPO) (Table 1). The vessels involved in AAV are 
typically capillaries, arterioles and venules, but small arteries and veins may also be affected. 
Autoimmunity is documented clinically by serum ANCAs against PR3 (PR3-ANCA) or 
MPO (MPO-ANCA), which are generally associated with the main syndromic AAV 
presentations (Box 1). AAVs collectively represent one of several types of autoimmune 
vasculitis (Figure 1). 
 GPA and MPA can involve small blood vessels in any organ or tissue, but commonly 
affect the upper and lower respiratory tract and the kidneys (Box 2). Patients with AAV 
typically present with severe organ-threatening or life-threatening disease, although less 
severe presentations also occur. GPA is predominantly associated with PR3-ANCA, and its 
clinical features typically include sinonasal disease, lower respiratory tract involvement with 
pulmonary haemorrhage and granulomatous inflammation, and glomerulonephritis. MPA is 
usually associated with MPO-ANCA, and clinical features include more severe renal disease 
and some of the manifestations of GPA but without granulomatous inflammation. EGPA is 
characterized by asthma, eosinophilia and, in many (but not all) cases, vasculitis. EGPA is 
less common than GPA or MPA and, in some cases, is associated with ANCAs, mainly 
MPO-ANCA (Table 1). Although categorized as a form of AAV, EGPA has less overlap with 
the other AAVs than that between GPA and MPA in its genetic, pathogenetic and clinical 
features, and management and is typically considered a separate entity. 
 Improvements in treatment and prognosis for patients with AAV have resulted from 
translation of both pre-clinical and clinical research findings. Here, we provide an updated 
overview of the clinical and molecular features of AAVs, present current pathophysiological 
concepts, discuss established and upcoming therapeutic options, emphasise the value of 
patient-oriented outcomes and provide a perspective on future challenges in AAV research 






Incidence and prevalence 
 Although fulfilling most definitions of a ‘rare disease’, with a historical estimated 
prevalence of 48–184 cases per million persons1, rheumatologists, nephrologists, clinical 
immunologists and other physicians regularly encounter patients with AAV. In fact, more recent 
studies report prevalence rates of 300-421 per million persons2,3, an increase likely explained by 
improving survival and better case definition. 
The global effects of AAVs in terms of premature mortality4, quality of life (QOL)5 and 
societal economic costs6 are considerable. Since the introduction of commercially available 
ANCA assays in the mid-1990s and enhanced physician awareness, there has been a noticeable 
apparent increase in AAV incidence. For example, the incidence rate of GPA between 1975 and 
2001 in Sweden increased from 3.3 to 11.9 cases per million persons per year7. The plateauing 
of incidence rates since then indicates that the true incidence has probably remained stable, 
although the lack of standardized diagnostic criteria may affect case ascertainment.  
 Wide geographical variation exists in AAV incidence (Figure 2), which is partly 
explained by methodological differences in study design, although specific patterns can be 
observed. First, GPA (PR3-AAV) mainly affects countries/regions in which the population is 
predominantly of European ancestry and is seldom observed in East Asian countries/regions. By 
contrast, MPA (MPO-AAV) predominates in Asian countries/regions, such as China and 
Japan8,9. Second, the incidence of GPA is influenced by latitude, as the incidence is lower 
towards the equator10,11. The disparity in incidence among ethnicities is further supported by 
studies examining multi-ethnic populations. Surveys in France and the USA indicate at least 
two-fold higher incidence of GPA and MPA in white populations than in other ethnicities12,13. A 
more recent UK study identified a similar signal, but this was mostly explained by the older age 
of the white population14. EGPA is strongly linked to asthma and eosinophilia in terms of both 
its clinical features and genetic make-up, although epidemiological data for EGPA are limited, 
as are data from Africa and South Asia for all types of AAV. It is unclear whether lack of access 
to ANCA testing in low-income and middle-income countries/regions is resulting in not only a 
lack of data but also under-diagnosis and under-treatment of AAV in these areas.  
 AAV in children is rare and less common than some other forms of vasculitis (including 
Kawasaki disease and IgA vasculitis). GPA seems to be more common than MPA or EGPA, and 






Risk factors and disease determinants 
Compelling evidence exists to implicate genetic factors in the pathogenesis of AAV, although 
genetic predisposition alone does not explain this complex disorder. As the age of onset typically 
ranges between middle to older age and there is an equal sex distribution in AAV prevalence, it 
is likely that environmental factors have a key role in AAV aetiology. Some epidemiological 
studies report a cyclical occurrence of GPA, which is consistent with an infectious trigger. 
Although the majority of studies describe an increase in the incidence of GPA in winter16-19, a 
higher summer incidence and no seasonal change have also been reported20,21. Indeed, increased 
rates of chronic Staphylococcus aureus nasal carriage observed among patients with GPA have 
been associated with an increased relapse risk22,23. 
 More granular epidemiological inspections of putative environmental causes are limited 
to small exploratory studies. An association between silica exposure and MPO-AAV has been 
consistently observed24,25. The high prevalence of silica in the natural environment (for example, 
in cement) is one proposed explanation for the apparent upsurge in AAV incidence following 
major earthquakes in 1995 and 2011 in Japan26,27. However, this correlation was not replicated 
in the aftermath of the 2011 earthquake in Christchurch, New Zealand28, a discordance that 
highlights the potential importance of AAV gene–environment interactions. Anecdotally, 
clinicians commonly observe a disparity in prevalence between urban and rural areas, although 
the epidemiological data to support this disparity are mixed29. For example, in a rural region of 
the UK, farming has been identified as a risk factor for both GPA and MPA24, indirectly 
implicating pesticide and fertilizer exposure as potential pathogenetic factors. By contrast, 
pollution, specifically carbon monoxide levels, has been associated with increased AAV risk in 
population-dense regions of China30. Other postulated risk factors include UV light31, smoking32, 
solvents24 and occupational solvent exposure24, but no single environmental factor seems to 
confer a major population-attributable risk. Similarly, specific drugs are responsible for some 
cases of vasculitis with syndromes similar to AAV (Box 3). 
 Ultimately, many epidemiological studies have treated AAV as a single disease construct 
and lack the power to examine the possibility that distinct environmental associations exist 






 AAVs are characterized by microvascular endothelial inflammation leading to 
extravascular inflammation, progressive injury, tissue destruction, fibrosis and loss of 
function. GPA and MPA develop by the loss of immunological T cell and B cell tolerance to 
one of two neutrophil proteins, PR3 or MPO. Mechanisms of acute injury in GPA and MPA 
are unique to this group of disorders (see Figure 3 for an overview). Specifically, loss of 
tolerance leads to the development of ANCAs, autoantibodies that activate neutrophils. 
ANCA-activated neutrophils localize to vulnerable microvascular beds, where they induce 
injury and release the autoantigen for presentation by antigen-presenting cells (such as 
dendritic cells (DCs)), allowing antigen recognition by effector T cells, which mediate further 
injury. Key elements of loss of tolerance, the generation of effector responses and 
mechanisms of microvascular injury are summarized in Figure 4 and Figure 5. 
 The pathogenesis of AAVs has been explored in in vitro assays and in vivo in animal 
models and in human studies. In animal studies, MPO-AAV is characterized by anti-MPO 
autoreactivity affecting the kidneys33. Although glomerular and pulmonary vessels are 
particularly vulnerable, there is little evidence to indicate why some vascular beds are 
preferentially involved. Furthermore, the mechanisms underpinning the frequent occurrence 
of granulomatous inflammation in PR3-AAV and its near absence in MPO-AAV are 
undefined. The response to injury, including the extent of tissue destruction and/or fibrosis, is 
likely to be contingent on the characteristics of the affected tissue and the intensity and 
chronicity of local vasculitic inflammation. 
 
Genetics 
GPA and MPA. Evidence for a genetic contribution to the aetiology of AAVs has come 
largely from registry studies, which revealed that the familial relative risk (RR 1.56) is 
similar to that for rheumatoid arthritis (RR 1.5-5.0) but lower than that for other immune-
mediated diseases34. Identifying robust genetic associations with AAV is challenging due to 
its fairly low prevalence, although candidate gene studies that utilized cohorts combining 
patients with GPA and those with MPA, and occasionally those with EGPA, found 
associations with the major histocompatibility complex (MHC) genes, in particular the HLA-
DPB1*04:01 allele in PR3-AAV35. The European Vasculitis Genetics Consortium reported 
the first genome-wide association study (GWAS) in AAV36, which identified both MHC and 
non-MHC associations with disease and demonstrated that GPA and MPA are genetically 




clinical syndromes per se, but with ANCA specificity. The Vasculitis Clinical Research 
Consortium37,38 confirmed these associations and provided the first evidence for genetic 
variants, for example in PTPN22, which are common to both PR3-AAV and MPO-AAV, 
suggesting that there is also a shared genetic component to these diseases. How much of the 
clinical similarity between the two syndromes is driven by this shared genetic architecture, 
rather than antigenic similarity, awaits the outcome of larger GWAS that are better powered 
to assess associations with PR3-AAV and MPO-AAV separately. 
 Although the causal variant or variants at each locus remain unresolved, these genetic 
studies shed light on the underlying disease pathogenesis. Some variants are in genes (such as 
PTPN22) that are associated with other autoimmune diseases39, and larger studies are likely 
to identify further commonalities. Other variants are more specific to AAV. Genetic variants 
in SERPINA1 (encoding α1-antitrypsin) or PRTN3 (encoding PR3) lead to increased plasma 
levels of PR3, suggesting that altered availability of circulating PR3 is a key driver in loss of 
tolerance to PR3 and the subsequent development of PR3-AAV40. The association of HLA-
DPB1*04:01 with PR3-AAV may simply reflect the role of HLA (MHC) molecules in 
presenting PR3 peptides to the immune system. However, this HLA-DP molecule also binds 
to the natural killer (NK) cell receptor NKp44 (also known as NCR2), leading to NK cell 
activation41, which might represent an alternative or additional mechanism that underpins the 
relationship between HLA-DP and PR3-AAV. 
EGPA. One GWAS examining EGPA identified 11 loci associated with EGPA42 and 
demonstrated that EGPA comprises two genetically distinct subtypes, MPO-ANCA+ EGPA 
and ANCA– EGPA, which align with the clinical differences between these patient 
subsets43,44. Some of the identified loci are associated with eosinophil count in addition to 
EGPA, and Mendelian randomization revealed that increased risk of eosinophilia underlies 
susceptibility to EGPA, with additional genetic or environmental factors required for the 
development of disease. 
 
Environmental factors and infections 
 The increasing incidence of AAV in the sixth and later decades of life implies a role 
for ageing-related factors and various accumulating environmental factors (discussed above), 
although these factors remain ill-defined. Whereas some observational studies implicate 
infectious triggers in AAV pathogenesis, the precise infectious agents remain unclear. 
Mechanistic in vitro and in vivo animal model studies suggest several ways in which infection 




by the formation of neutrophil extracellular traps (NETs) that may be resistant to degradation 
in AAV45, by molecular mimicry (that is, microbial antigens sharing sequence similarity with 
a host protein) and by the priming of neutrophils for ANCA-induced activation33 (Figure 4). 
Some attention has focused on S. aureus, with reports of increased rates of nasal carriage in 
relapsing patients with GPA22 and experimental data implicating a plasmid-encoded 6-
phosphogluconate dehydrogenase sequence from some S. aureus strains by molecular 
mimicry in MPO-AAV46 
 
ANCA antigens 
 As autoreactivity to either MPO or PR3 is central to pathogenesis in the majority of 
cases of AAV, the characteristics of the key autoantigens are important. In most patients with 
AAV, there is a single dominant autoantigen. PR3 and MPO are found primarily in 
neutrophils and are also produced by monocytes and macrophages. Although PR3 and MPO 
are mainly synthesized by immature neutrophils, altered DNA methylation and increased 
expression of PRTN3 and MPO in mature neutrophils is implicated in disease pathogenesis47. 
PR3 and MPO are not only key AAV autoantigens but they also have damaging effects on the 
endothelium in microvascular inflammation. They are released by multiple mechanisms, 
including by degranulation and microparticle release, and as constituents of NETs48. 
 PR3 is a 29kDa serine protease with a pro-form and a mature form49, which are 
located within azurophilic granules. The variable expression of PR3 on the surface of 
neutrophils is in part dependent on co-expression with CD177, which binds to and colocalizes 
with the 2-integrin CD11b as part of the CD11b–CD18 complex50,51. Cell surface PR3 
expression is increased in apoptotic neutrophils, which limits their phagocytic clearance by 
macrophages and promotes a pro-inflammatory microenvironment49. MPO is abundant in 
human neutrophils as a major component of azurophilic granules. Mature MPO is a highly 
cationic homodimeric glycoprotein consisting of light and heavy chains, bound to a haem 
group. The heavy chain is extensively but variably glycosylated52,53. Pro-inflammatory 
stimuli increase cell surface MPO levels, and MPO is released in inflammatory states, where 
it catalyses the formation of reactive intermediates, including hypohalous acids. Although the 
AAVs are typically considered systemic autoimmune diseases, each with dominant 
autoreactivity to only a single autoantigen, other autoantigens have been associated with 
AAV. These autoantigens include lysosome-associated membrane protein 2 (LAMP2)54, 




pentraxin 361. Infection has been implicated in loss of tolerance to some of these antigens. In 
rats, an epitope in LAMP2, an endolysosomal protein found in myeloid cells and endothelial 
cells, is identical to part of the bacterial adhesin FimH and induces AAV54. [Reactivity to 
cPR3 peptides, which are derived from the non-coding strand of PR3 cDNA and potentially 
produced after infection55, may trigger anti-PR3 autoreactivity. Although several studies 
support a role for LAMP2 in MPA or GPA, or cPR3 in the pathogenesis of PR3-AAV, not all 
reports implicate these alternative antigens in disease62,63. 
 
Loss of tolerance to ANCA antigens 
Central and peripheral mechanisms of tolerance. Central and peripheral mechanisms 
prevent damaging autoreactivity and autoimmune diseases by maintaining tolerance to self-
antigens. In most autoimmune diseases, loss of T cell tolerance allows the emergence of T 
helper (TH) cells that are crucial for autoantibody production by cells of the B cell lineage and 
also promote tissue injury themselves. Loss of B cell tolerance allows the emergence of 
autoreactive B cells and plasma cells that produce damaging autoantibodies. Memory T and 
B cells that develop over time are important in chronicity and relapse, as occurs in AAV 
(Figure 4). Loss of tolerance to neutrophil proteins occurs prior to the onset of AAV 
symptoms64. Our understanding of this process is imprecise; whereas dysregulated neutrophil 
apoptosis might predispose to loss of tolerance, there is no clear evidence that this is 
essential. Defects in both central and peripheral tolerance are present in AAV. Central 
tolerance to antigens in AAV is imperfect, as autoantigen-specific T cells and ‘natural’ 
autoantibodies are present in healthy individuals65. In the thymus, which is crucial for T cell 
tolerance, MPO expression is under the control of autoimmune regulator (AIRE) and Aire-/- 
mice exhibit increased autoimmunity to MPO66. However, AIRE-deficient individuals do not 
seem to develop AAV, consistent with the existence of multiple layers of tolerance to MPO. 
Animal studies support a role for regulatory T (Treg) cells in limiting autoimmune disease
66. 
Furthermore, patients with AAV have functionally defective Treg cells and fewer regulatory B 
(Breg) cells than healthy individuals. Their Treg cells have a diminished capacity to suppress 
effector responses ex vivo67-70, with these abnormal Treg cells having an effector T helper 
(TH17)-like phenotype. At least some being antigen-specific
68,71. To better understand loss of 
tolerance and to move towards harnessing tolerogenic therapeutic platforms and developing 
more precise diagnostic tools and biomarkers, immunodominant T cell and B cell epitopes 
have been defined for MPO but not for PR371-74. Conformational and linear B cell epitopes 




epitope overlaps with a linear B cell epitope and a CD8+ T cell epitope71-74, and is 
nephritogenic in mice. Knowledge of these epitopes enables translational strategies to 
improve disease monitoring and re-establish tolerance. 
 
Maintenance of autoreactive B cells. After the loss of tolerance, the survival of autoreactive 
lymphocytes promotes ongoing and chronic disease (Figure 4). In the case of AAV, the B cell 
survival factor B cell-activating factor (BAFF; also known as TNFSF13B and BLyS) is 
produced by ANCA-stimulated neutrophils, and serum BAFF levels are elevated in patients 
with AAV78,79, suggesting that interactions between BAFF and its receptors on autoreactive B 
cells and plasmablasts promote autoimmunity. After therapeutic B cell depletion, BAFF may 
promote relapse by stimulating the recovery of autoreactive B cells. B cells and B cell 
aggregates are present in more chronic lesions, implying additional roles for antigen-specific 
B cells beyond antibody production, either as pro-inflammatory cells or as antigen-presenting 
cells80,81. 
 
The role of ANCA and neutrophils 
ANCAs activate neutrophils and monocytes. 
 A critical consequence of loss of T and B cell tolerance is the production of ANCAs 
that bind to and activate neutrophils, so that they adhere in vulnerable microvascular beds and 
induce injury (Figure 3; Figure 5). ANCAs are usually of the IgG isotype, but IgA and IgM 
isotypes have also been reported82,83. ANCAs bind to their autoantigen, activate neutrophils 
and initiate injury84. In vitro studies support a model whereby both ANCA F(ab')2 fragment–
antigen and Fc–FcR interactions are required for neutrophil activation, by G-protein-coupled 
pathways and SYK, respectively85,86. The effects of ANCAs on neutrophils include changes 
in adhesion molecule expression87,88, alterations in cytoskeletal proteins (such as 
polymerization of F-actin)89 and the generation of reactive oxygen species90. The release of 
inflammatory mediators occurs by several mechanisms, including degranulation, NET 
formation and the release of microparticles91. The release of cytokines, proteases and other 
molecules induces necrotizing crescentic glomerulonephritis in mice92. A report of placental 
MPO-ANCA transfer to a neonate with pulmonary haemorrhage and microscopic haematuria 
supports a role for ANCAs in AAV pathogenesis93. The in vivo pathogenicity of ANCA-
activated neutrophils has been convincingly demonstrated in experimental MPO-AAV92,94 




monocytes ex vivo, as monocytes express PR3 and MPO, albeit at lower levels than 
neutrophils. Compared with studies in neutrophils, the pathogenic implications of any direct 
effects of ANCAs on monocytes is less certain97,98. Whether the 5–10% of patients with GPA 
or MPA who are ANCA– have a relevant autoantibody is unresolved. Patients may be MPO-
ANCA+ but their ANCAs may bind to an epitope that is masked in conventional assays73 or 
to other antigens, including LAMP2 (ref.99) or pentraxin 3 (ref.61). There are ANCA epitopes 
that are derived from pathogenic sequences as well as from endogenous proteins, while other 
factors, including ANCA sialylation and glycosylation, may contribute to the inconsistent 
relationship between ANCA seropositivity and disease activity73,100,101.  
Neutrophil priming and activation state. Although ANCAs may activate neutrophils 
without additional inflammatory signals, neutrophil priming by exogenous or endogenous 
pro-inflammatory signals promotes the damaging effects of these cells after ANCA-induced 
activation (Figure 3, Figure 4). In addition to the functional consequences of genetic variation 
in PRTN3 and its inhibitor SERPINA140 and epigenetically mediated increases in PR3 and 
MPO expression47,102, neutrophils from patients with AAV, even from those in remission, 
produce more intracellular ROS, display greater NET release and have a greater capacity to 
active the alternative pathway of complement (see below)103,104. The relative contribution of 
neutrophil intrinsic properties versus their response to priming events is unclear, but both are 
likely to be relevant. Neutrophil priming in AAV occurs by several mechanisms, of which the 
most well defined are the complement system (see below), Toll-like receptor (TLR) 
signalling and cytokines (including TNF and IL-18)33. TLRs are expressed on several 
relevant cell types, including neutrophils, monocytes and microvascular endothelial cells. 
Engagement of TLRs by pathogen-associated molecular patterns (PAMPs) or in sterile 
inflammation by damage-associated molecular patterns (DAMPs) activates neutrophils and 
the endothelium105-108. 
Complement activation via the alternative pathway. Complement, specifically the C5a 
receptor (C5aR), is a validated therapeutic target in acute AAV109-111. Evidence implicates 
neutrophil cell surface C5a–C5aR interactions in neutrophil priming and activation109,112-115. 
Although paracrine and autocrine sources of C5a are possible, circulating C5a may be more 
important116, and little evidence exists for a role for the membrane attack complex (which 
comprises the complement subunits C5b, C6, C7, C8 and C9)109 in neutrophil priming and 
activation. In addition to activating neutrophils, C5a enhances neutrophil retention in the 
microvasculature and promotes antigen recognition by T cells by activating dendritic cells115. 




activation, and in AAV evidence points to the alternative pathway being the key to 
pathological C5a–C5aR interactions. In mice, deficiency of factor B (which is important for 
the alternative pathway), but not C4 (which is important for the classical and lectin pathways) 
was protective in experimental anti-MPO antibody-induced glomerulonephritis112, while 
factor Bb immunostaining in glomeruli correlated with renal injury117. Although not 
prominent, complement deposition is present in the kidneys of some patients with AAV and 
may also be relevant to tissue pathology118. Low serum C3 levels in patients with AAV with 
renal involvement are associated with unfavourable outcomes119,120. Other potential roles for 
complement in AAV include tissue-damaging interactions with pattern recognition receptors 
and with pro-coagulant molecules118.  
ANCA-induced neutrophil recruitment to the microvasculature. ANCA-activated 
neutrophils mediate microvascular injury by adhering to microvascular endothelial cells in 
vulnerable tissues, mediated by integrin–endothelial adhesion molecule and chemokine–
chemokine receptor interactions (Figure 5). ANCAs enhance contact between neutrophils and 
activated endothelial cells via 2 integrins and CXC chemokine receptor 2 (CXCR2) in flow 
chamber assays121. In vivo microscopy studies using inflamed post-capillary venules showed 
incremental recruitment of ANCA-activated neutrophils, consistent with the aforementioned 
mechanisms elucidated in vitro122,123. However, in the glomerulus, the mechanisms of 
ANCA-induced neutrophil adhesion are dependent on the ANCA concentration, with 
adhesion mediated by 2-integrin at low ANCA levels and by 4-integrin at high ANCA 
levels, but without additional stimuli (such as lipopolysaccharide) that themselves induce 
leukocyte recruitment to glomeruli88. 
 
T cells and cellular immunity 
 In addition to humoral immunity, cellular immunity is important in AAV 
pathogenesis, as CD4+ T cells promote ANCA production and CD4+ T cells and CD8+ T cells 
recognize ANCA antigens deposited in peripheral tissues by activated neutrophils (Figures 3 
and 5). The class-switched, high-affinity nature of IgG ANCA implies T cell help by T 
follicular helper (TFH) cells
124, the abundance of which is increased in patients with GPA125. 
CD4+ effector memory T cell abundance is increased in the blood and urine in patients with 
AAV126 and CD4+ T cells and CD8+ T cells are present in lesions127-129. Both TH1 and TH17 
effector cytokine profiles have been observed in patients with AAV130,131, including TH1 




patients with GPA are linked to cytomegalovirus (CMV) infection, which is itself associated 
with poor AAV outcomes133. Furthermore, subclinical CMV infection and reactivation in 
immunosuppressed patients with AAV may impair immune responses to infection, as the 
antiviral drug valacyclovir improved vaccine responses in CMV-seropositive patients with 
AAV134. 
 Analyses of CD8+ T cell transcriptomes of patients with active AAV at diagnosis 
reveal that patients can be stratified into two groups correlating with differences in long-term 
outcomes135. CD8+ T cell and CD4+ T cell transcriptome data shows that reduced expression 
of genes linked to T cell exhaustion correlates with relapsing disease136. The correlation 
between exhaustion, with progressive loss of effector T cell function, and favourable disease 
outcome extends across a range of autoimmune and autoinflammatory diseases136 and implies 
that therapeutics targeting this process may improve the management of AAV. 
 Effector T cells participate in tissue injury in AAV. When ANCA-activated 
neutrophils localize to inflamed tissues, they release their autoantigen129,137. The widespread 
deposition of the autoantigens in inflamed tissues in AAV makes these antigens available for 
recognition by effector T cells. Experimental studies, mostly in a mouse model of MPO-
ANCA-induced glomerulonephritis, demonstrate a role for both MPO-specific TH17 cells 
(earlier) and TH1 cells (later)
138, while CD8+ T cells also cause experimental injury74. 
 
Monocytes and macrophages 
 Macrophages are prominent in AAV lesions, are the most abundant immune cell type 
in glomeruli128,129, and are important in both acute and chronic injury (Figure 5). ANCAs 
bind to intermediate monocytes that release pro-inflammatory cytokines and chemokines97,98, 
while in a mouse model of MPO-ANCA-induced glomerulonephritis, inflammatory 
monocytes participate in glomerular crescent formation139. Macrophages are activated by 
effector TH1 and TH17 cells at sites of injury, participate in granuloma formation and form 
macrophage extracellular traps in tissues129, and in chronic inflammation, profibrotic 
macrophages contribute to disease progression and damage. 
 
The pathogenesis of EGPA 
The pathogenesis of EGPA is not well understood but is likely to be substantially 
different to both GPA and MPA, although the extent of the similarities and differences is 
unclear. Furthermore, the differing clinical presentations, genetic associations and response to 




pathogenesis of these forms of EGPA42-44. Genetic associations with genes that influence 
eosinophil numbers and those that underlie asthma are shared by both groups of patients. 
However, in ANCA–patients with EGPA, the association with genes affecting barrier function 
(including GPA33) implies a role for mucosal dysfunction, whereas in MPO-ANCA+ patients 
with EGPA, the HLA associations are consistent with MPO-ANCA+ EGPA being an 
eosinophilic autoimmune disease. 
In addition to genetic studies, observational studies implicate eosinophil dysfunction in 
the pathogenesis of EGPA. Eosinophil-mediated injury by the release of granule proteins can 
induce tissue-resident cells to release pro-inflammatory mediators. Some of these tissue cell-
derived molecules, such as IL-25, affect both adaptive immune cells (type 2 T helper (TH2) 
cells) and innate immune cells (group 2 innate lymphoid cells (ILC2s))140. Both TH2 cells and 
ILC2s produce IL-5 and IL-13, which are key cytokines that promote eosinophil proliferation 
and function141,142. The role of IL-5 has been validated by trials of the anti-IL-5 monoclonal 
antibody mepolizumab in patients with EGPA143. TH2 cell-associated chemokines, such as CC-
chemokine ligand 26 (CCL26; also known as eotaxin 3), enhance eosinophil recruitment142. 
Other T cell-associated cytokines are also elevated in patients with EGPA, but to date there is no 
clear evidence that a particular pattern of cytokine or chemokine production characterizes MPO-
ANCA+ or ANCA- EGPA. A direct relationship between MPO-ANCA and eosinophils has not 
yet been demonstrated in MPO-ANCA+ patients with EGPA. 
 
Chronicity and relapse in AAV 
The pathogenesis of AAV is characterized by complex pathways to tissue injury and 
damage involving both humoral and cellular effector systems. Much of the work on the 
pathogenesis of AAV has been in systems modelling acute injury. Although largely 
unexplored, mechanisms operative in disease induction are also likely to be relevant to 
relapse. Some observational evidence points towards infection, in part related to chronic 
sinonasal mucosal damage, being important in relapse, and determinants of T cell activity and 





Diagnosis, screening and prevention 
Diagnostic and classification criteria 
 Clear definitions of GPA, MPA, EGPA and other systemic vasculitides are provided by 
the updated 2012 Chapel Hill Consensus Conference (CHCC)145, which, as the name implies, 
was consensus- rather than data-driven (Figure 1, Table 1). In 2006, an algorithm was developed 
for applying the 1990 American College of Rheumatology (ACR) classification, 1993 CHCC 
definitions and ANCA specificity to streamline classification of patients with GPA, MPA and 
EGPA for epidemiological studies and clinical trial purposes, but cannot be regarded as 
providing diagnostic criteria for clinical practice146. The current Diagnostic and Classification 




 The different types of AAV share non-specific clinical features of systemic 
inflammation, such as weight loss, malaise, fatigue, arthralgia and myalgia, which relate to 
the systemic autoimmune pathophysiology (Box 2, Figure 6). AAVs are frequently initially 
misdiagnosed as infections, malignancies, depression or osteoarthritis, especially in older 
patients148. This is pertinent, as some conditions, such as infective endocarditis, not only 
share clinical features with AAV but may also have a positive ANCA test by indirect 
immunofluorescence (see Box 1). Although asthma is a typical early feature of EGPA, all 
forms of AAV can present with manifestations relating to small vessel vasculitic lesions and 
dysfunction of any organ149. Various organ systems and tissues are affected in AAV, albeit at 
different frequencies in GPA, MPA and EGPA (Figure 6). 
Necrotizing or granulomatous lesions can affect the ear, nose and throat (ENT) tract, 
and cause symptoms of chronic rhinitis, sinusitis or laryngitis. Similar processes in the 
respiratory tract, including pulmonary capillaritis, present as shortness of breath, cough and 
haemoptysis due to pulmonary haemorrhage (Figure 6). Cavitating lung nodules can be 
present. Ophthalmological manifestations include granulomatous orbital or retroorbital 
masses, anterior segment inflammation, retinal vasculitis or optic neuritis. A purpural or 
petechial rash is the most common dermal manifestation, with necrotizing dermal vasculitis 
and other non-vasculitic skin rashes also occurring. Kidney involvement usually presents as 
rapid-progressive glomerulonephritis with haematuria, proteinuria and hypertension. 




peripheral nervous system is typically affected by mononeuritis multiplex, due to focal 
vasculitis of the vasa nervorum. 
EGPA is characterized by the near-universal presence of asthma, often for years prior 
to the onset of eosinophilia and eosinophilic tissue inflammation, and difficult to control 
asthma not infrequently persists even after treatment of EGPA. A subset of patients with 
EGPA do exhibit frank vasculitis. The tissues affected in EGPA are similar to those affected 
to GPA and MPA, albeit at different frequencies (Figure 6). In particular, cardiomyopathy 
due to eosinophilic myocarditis is not uncommon in EGPA and can be life-threatening. Some 
of the differences in the manifestations of EGPA and MPA or GPA, such as urticaria and 
eosinophilic pneumonia, align with its characteristic eosinophil-dominated inflammation. 
Some patients with GPA or MPA present with vasculitis limited to a single organ, 
such as the kidneys, ENT tract or lungs, which may represent the early stages of AAV. 
However, in MPO-ANCA+ patients with MPA, isolated renal disease or isolated pulmonary 
fibrosis is not infrequent. The recognition of pulmonary fibrosis as a feature of MPA in 
MPO-ANCA+ patients, often as the sole manifestation of disease, has been of some 
interest150. This presentation may be more common in Japan151,152, although it does occur in 
diverse geographical locations. MPO-ANCA-associated pulmonary fibrosis may result from 
chronic low-grade pulmonary inflammation, but this is not clear. A minority of MPO-ANCA+ 
patients with MPA also have anti-glomerular basement membrane antibodies and exhibit a 
hybrid disease phenotype153, whereas individuals with systemic lupus erythematosus or 
systemic sclerosis can be MPO-ANCA+ and develop some features of AAV, especially the 
vasculitic pattern of glomerulonephritis154-156. As initial clinical presentations are diverse and 
often nonspecific, AAV is an infrequent but important differential diagnosis for many 
conditions across many medical disciplines. AAV can remain undiagnosed for months or 
years until ANCA testing is performed. In view of the rarity of AAV and the existence of 
mimics of vasculitis, the diagnosis should be reviewed periodically, particularly in cases of 
inadequate response to treatment or if not all disease manifestations are consistent with AAV. 
 Children with AAV can develop a similar range of clinical features to adults. 
Constitutional, ENT, renal and pulmonary manifestations are most commonly found at 
presentation15. However, some features may be more common in children. For example, a 
French Vasculitis Study Group Registry-based case control study, with most children having 
GPA, found that children were more likely to have fever at onset than adults157. Rates of renal 




Children were more likely to relapse than adults and more frequently accrued damage, 
especially ENT damage, over time15,157. 
 
Clinical syndromes and antigenic specificity 
 MPA and GPA are strongly associated with MPO-ANCA and PR3-ANCA, respectively, 
whereas EGPA can be either ANCA+ (mostly MPO-ANCA) or ANCA– (Table 1). Global 
variations in clinical manifestations reflect the relative rates of MPA (MPO-AAV) and GPA 
(PR3-AAV) discussed in Epidemiology (above), with, for example, clinical features associated 
with MPA being more common in East Asia. Given the presence of overlapping signs and 
symptoms but also clear clinical differences (described in Table 1 and Box 2), another approach 
to disease classification is by the autoantigen involved (that is, PR3-AAV and MPO-AAV), 
although this approach also has limitations: ANCA can be negative, MPO-ANCA can be false 
positive in patients without vasculitis158, assay standardization is lacking, and not all countries 
have ready access to high-quality assays. Nonetheless, genetic and other studies demonstrate that 
the clinical differences between PR3-AAV and MPO-AAV are greater than those between GPA 
and MPA36,159, indicating that, from a pathogenetic perspective, antigen specificity is important. 
Furthermore, post hoc analyses of a large multicentre study suggest that PR3-ANCA+ patients 
may respond better to the biologic agent rituximab than to the immunosuppressants 
cyclophosphamide and azathioprine, whereas these treatments seem to be equally effective in 
MPO-ANCA+ patients160. ANCA specificity also predicts differences in long-term prognosis: 
PR3-ANCA+ patients are at higher risk of relapse than MPO-ANCA+ patients161. In EGPA, the 
presence or absence of ANCA in patients defines its two subtypes. Most patients with EGPA are 
ANCA-, but ~40% are (or have been) ANCA+, almost always MPO-ANCA. Clinically, renal 
involvement and peripheral nerve involvement are more common in ANCA+ patients with 
EGPA, with cardiomyopathy and possibly pulmonary infiltrates being more common in those 
who are ANCA– 43,44. 
 
Biomarkers 
 ANCAs are unique markers that support the classification and diagnosis of GPA, MPA 
and EGPA. The indirect immunofluorescence test has been the initial screening test for ANCA, 
but high-quality immunoassays are preferred162 (Box 1). The ANCA test is useful in monitoring: 
patients with persistently elevated ANCA, as those with a reappearance of ANCA or an increase 
in ANCA levels have an increased likelihood of relapse, although restarting or intensifying 




earlier relapse and a higher frequency of memory B cells163, while a higher plasmablast 
percentage during remission is also predictive of relapse164. The acute-phase markers C-reactive 
protein and erythrocyte sedimentation rate are of limited use in evaluating disease activity due to 
their lack of specificity. Other disease activity biomarkers, including urinary soluble CD163, are 
under evaluation for use in assessing disease activity but await validation for routine clinical 
use165-167. 
 
Assessment of disease activity and chronic damage 
 Patients with AAV should have access to medical specialists with expertise in the 
complex care of vasculitis, ideally in a multidisciplinary context. Where needed, early referral to 
specialists experienced in assessing specific organ systems involved in AAV improves the 
quality of disease assessment. Managing patients at, or in collaboration with, a dedicated 
vasculitis centre provides opportunities to participate in clinical trials. Disease assessments in 
AAV should target activity, damage, prognosis and function or QOL168. Validated tools to assess 
disease activity include the Birmingham Vasculitis Activity Score (BVAS) and the Five Factor 
Score (FFS). The BVAS comprises ten systems (one general, eight organ-specific and one open) 
and is used in clinical research to assess disease activity, remission, response to therapy and 
flare169. Only items that are newly present or worsening over the preceding four weeks are 
recorded. Disease states of active disease, remission, and refractory disease are defined as 
follows: a BVAS score of 0 represents remission, ≥1 represents active disease, and refractory 
disease is active disease despite treatment. Consensus definitions have been recommended by 
the European League Against Rheumatism (EULAR) for disease activity states, including 
remission, response, refractory disease and relapse, which can be useful for clinical trials and 
studies170. The 1996 FFS is based on serum creatinine, proteinuria, cardiomyopathy, 
gastrointestinal involvement and central nervous system involvement, and has been validated for 
MPA and EGPA but not GPA. The revised 2009 FFS includes serum creatinine, age (>65 years), 
cardiomyopathy, gastrointestinal involvement and absence of ENT manifestations (GPA and 
EGPA only) but this version requires validation171. To assess chronic damage, both from the 
disease itself and from treatments, such as glucocorticoids, the Vasculitis Damage Index (VDI) 
predicts mortality risk and scores 10 systems, namely musculoskeletal, skin and mucous 
membranes, ocular, ENT, pulmonary, cardiovascular, the peripheral vasculature, 





 The BVAS and VDI are approved by the Outcomes Measures in Rheumatology 
(OMERACT) group and EULAR as key outcome measures to record disease activity and 
damage, respectively, in clinical trials173. Measures of QOL are important in the assessment of 
AAV. Generic tools have thus far been used but AAV-specific instruments have been developed 
(see QOL section, below).  
 
Association with cardiovascular events 
 Increased risk of cardiovascular event has been documented in patients with AAV174. 
Indeed, during 5-years of follow up of four European Vasculitis Study Group trials of GPA and 
MPA, a cardiovascular event, defined as cardiovascular death, stroke, myocardial infarction, 
coronary artery bypass graft, or percutaneous coronary intervention, occurred in 14% of patients. 
PR3-ANCA+ status was associated with a reduced cardiovascular risk compared to MPO-
ANCA+ or ANCA– status175. 
Dysfunction of the immune and coagulation systems contribute to an increased risk of 
venous thromboembolism176, especially during active disease177. An increased incidence of 
venous thromboembolism, in both typical and atypical sites, and pulmonary embolism has also 
been reported in GPA, MPA and EGPA178. 
 
Role of imaging and biopsy 
 A chest X-ray helps dissect the underlying pathology in patients with pulmonary 
symptoms (Figure 6), although CT has a higher sensitivity in detecting pulmonary nodules, 
cavities and alveolar opacities, as well as masses in the retro-orbital space, paranasal sinuses and 
the mastoids179. Iodinated contrast agents are not required for these studies. High-resolution CT 
(HRCT) of the chest may be helpful for detecting interstitial pneumonia; a study of HRCT 
involving Japanese patients with MPA, all but three of whom were MPO-ANCA+, demonstrated 
abnormalities in 93% of patients, with 51% having interstitial pneumonia152. Although dynamic 
expiratory CT and other modalities have been advocated as potentially useful in detecting 
subglottic stenosis or endobronchial disease180, advanced imaging techniques may not be widely 
available or may only be available as research tools. 
The high diagnostic specificity for AAV of a positive ELISA test for MPO-ANCA or 
PR3-ANCA may, in the appropriate clinical setting, preclude the need for biopsies. However, 
renal, lung, skin or other tissue biopsy is often important in establishing the diagnosis and may, 
especially in the case of nasal biopsy, provide the first evidence for AAV, particularly GPA. In 




glomerulonephritis are more specific for AAV than dermal leukocytoclastic vasculitis. 
Ultrasonography-guided percutaneous kidney biopsy, although not mandatory, in the presence of 
haematuria and/or proteinuria can help make an initial diagnosis of AAV. Kidney biopsy can 
also be used to diagnose relapse, establish the degree of chronicity of nephritis and, in chronic 
disease, may be useful in determining whether impaired kidney function and proteinuria is 
related to active vasculitis or irreversible damage. Biopsy samples from patients with suspected 
AAV should be assessed by an experienced pathologist. 
 
Pathology 
 Although sharing many features, the different forms of AAV show histopathological 
differences (Figure 7). Fibrinoid necrosis and inflammation of small vessels, sometimes 
accompanied by thrombosis, is the hallmark of acute injury in all forms of AAV181. In MPA, 
these features are present without other defining features, such as the granulomas in GPA or the 
prominent eosinophilic infiltrates in EGPA. Chronic lesions are characterized by transmural 
scarring with loss of the elastic internal lamina. Larger blood vessels can be affected, with 
leukocytic infiltrates and fibrinoid necrosis, as seen in polyarteritis nodosa. However, the 
involvement of larger vessels should not be interpreted as an ‘overlap’ with other forms of 
vasculitis when small-vessel (capillary and arterioles) involvement is also present. Although the 
histopathology of EGPA features necrotizing small-vessel vasculitis (as in GPA and MPA), an 
abundance of eosinophils is its defining feature. In the early stages of disease, eosinophilic 
infiltrates (but no necrosis) are present in tissues or in blood vessel walls, whereas in later stages 
of disease, eosinophils also surround the epithelioid cells within granulomas, and necrosis is 
present. 
Renal involvement. In the kidneys, the characteristic lesion in AAV is segmental necrosis of 
glomerular capillary loops, with little or no deposition of immunoglobulin or complement, 
termed ‘pauci-immune’ focal necrotizing (and crescentic) glomerulonephritis. Different lesions 
in different glomeruli within the same biopsy specimen reveal the asynchronous nature of the 
vasculitic injury. Acute glomerular injury is characterized by segmental necrosis with 
extravasation of fibrin and erythrocytes into the urinary space, followed by proliferation of 
parietal glomerular epithelial cells forming a cellular crescent. Destruction of Bowman’s 
capsule, the basement membrane surrounding the glomerulus, results from glomerular and 
periglomerular inflammation. These inflammatory changes lead ultimately to glomerulosclerosis 




 Glomerular lesions are used to stage renal disease in AAV by a histopathological 
classification182, where the dominant lesion is linked to outcomes. There are four patterns of 
injury, namely sclerotic (≥50% globally sclerosed glomeruli, worst outcome), focal (≥50% 
normal glomeruli, best outcome), crescentic (≥50% cellular crescents, intermediate outcome) 
and mixed (no single dominant type of lesion, outcome better than the sclerotic but worse than 
the crescentic class). In clinical settings, this classification has been validated by some but not all 
studies, especially with regard to prognosis in the crescentic and mixed classes183. The 
classification does not currently include the extent of tubulointerstitial lesions or renal function. 
A further classification system has been proposed that includes these factors, together with the 
proportion of normal glomeruli at biopsy184. 
 Glomerular injury is often accompanied by inflammation of small arteries and a variable 
interstitial infiltrate around necrotic lesions, either glomeruli or blood vessels, in a granuloma-
like pattern, but multinucleated giant cells are rarely seen. The presence of sarcoid-type 
granulomas in renal biopsy specimens should lead to consideration of other diagnoses, such as 
renal sarcoidosis or an allergic drug reaction. 
Respiratory tract involvement. In GPA, upper and lower respiratory tract injury classically 
involves granulomatous inflammation. Small granulomas are composed of sometimes loose 
aggregates of epithelioid cells. The granulomatous inflammation often shows central necrosis 
containing nuclear fragments of granulocytes, is surrounded by a palisade of epithelioid cells 
and, in EGPA, by large numbers of eosinophils. Granulomatous inflammation and areas of 
necrosis are often confluent, with a ‘geographic’ appearance at low magnification. 
Multinucleated giant cells are almost invariably present and are pathognomonic for GPA or 
EGPA when seen in isolation in lung or upper airway biopsy samples, cytology specimens from 
bronchoalveolar lavage or nasal swabs taken when clinical features suggestive of AAV are 
present.  
 In the lungs, neutrophilic capillaritis is common to all forms of AAV. As vasculitic 
changes can be difficult to detect in small biopsy samples, samples should also be stained with 
trichrome and Elastica van Gieson for optimal detection of any disruption to alveolar or vessel 
walls, small areas of necrosis in arterioles and arteries, vascular inflammation and characteristic 
scars affecting the full thickness of the vessel wall, indicating past injury. Acute injury may 
consist of only non-specific inflammation or features resembling bronchiolitis obliterans and 
organizing pneumonia. However, signs of recurrent alveolar haemorrhage with extravasation of 
erythrocytes, variable numbers of siderophages or small areas of fibrin, necrosis or micro-




can cause severe soft tissue destruction, including of the nasal cartilage. Large ulcers with 
denuded epithelium can be seen. Granulomatous inflammation is also a feature of nasal 
involvement in EGPA, sometimes with eosinophilic necrosis but more often containing 
epithelioid cell aggregates surrounded by a dense eosinophil infiltrate. 
Other organ and tissue involvement. Similar vasculitic changes are found in other tissues, 
such as the heart, brain or gastrointestinal tract. In the gut, the finding of otherwise unexplained 
necrosis or haemorrhagic infarction should prompt extensive examination of mesenteric vessels 
for vasculitis. Although most often seen in isolation, dermal leukocytoclastic vasculitis can 
represent systemic disease. Involvement of the peripheral nervous system as mononeuritis or 




 The 5-year survival rates for AAV have been steadily rising to around 70–80% over the 
past 40–50 years, following the introduction of immunosuppressant therapies, increasing 
proficiency in the their use and the introduction of ANCA testing, which are promoting earlier 
diagnosis and improvements in supportive care186. Data also suggest that there are ongoing 
improvements in mortality and end-stage kidney disease rates over the past decades in the 
USA187,188. Globally, AAV mortality rates, based on the International Classification of Diseases 
10th Revision (ICD-10) data, are falling189. These data, though imperfect, include mortality rates 
from many countries and suggest, using 2014 data, similar age-standardized mortality rates in 
North America and Europe, with lower rates in Latin America and higher rates in Oceania. Data 
from Asia and Africa were limited. 
Initial clinical factors influencing outcomes include older age, severity of renal 
dysfunction, the presence of pulmonary haemorrhage (in some series) and disease activity 
measured by BVAS186; the findings on renal biopsy reflect severity of renal dysfunction and 
correlate with outcomes182. The 2009 FFS can also be applied to prognosis, since four factors are 
associated with a poor prognosis (age, renal insufficiency, cardiac involvement, and 
gastrointestinal manifestations, where each is accorded +1 point); the fifth factor, ENT 
manifestations, is associated with a better outcome, and the absence of ENT symptoms scores 1 
point171. Ongoing factors influencing survival include infectious burden, development of first 
relapse within one year and the amount of chronic damage measured by the VDI175. As the VDI 
encompasses both disease and treatment-related damage, the risks of immunosuppressant drugs 




presence of PR3-ANCA and upper or lower respiratory involvement, seem to increase the 






 Following diagnosis, disease assessment in AAV should consider activity and damage 
(tools for assessing activity and damage are discussed earlier), prognosis (see above) and 
function or QOL (described below). Broadly speaking, therapy can be divided into a phase 
aiming to induce remission with more intense therapy and a subsequent period where the goal 
is to maintain remission (Figure 8; clinical trials in GPA and MPA are summarized in Table 2 
and Table 3). The goal of induction therapy is to achieve remission by three months that is 
then sustained. Later remission, early relapse or refractory disease is associated with worse 
outcomes191. 
 Treatment should be initiated as soon as a diagnosis of AAV is at least probable and 
appropriate safety investigations have been performed, as delays in diagnosis and treatment 
lead to worse outcomes. Initiation of treatment, especially in the setting of severe renal or 
lung disease, should not be delayed by the need to obtain a biopsy, as several days of 
treatment usually does not markedly reduce the diagnostic yield of a biopsy. 
 
Remission induction 
 Prior to initiation of therapy, there should be an assessment of any concurrent 
infection and any risk of infection, including chronic viral infections (which should be 
screened for) or immunodeficiency, and for conditions, such as diabetes mellitus, 
osteoporosis and psychiatric disorders, that increase risk of glucocorticoid-associated adverse 
events. 
Glucocorticoids. Oral glucocorticoids (such as prednisone, prednisolone and others) are 
commenced when a diagnosis of AAV seems probable. These drugs exert a rapid effect. The 
initial dose for severe disease is 1 mg/kg daily of prednisone (or equivalent). The PEXIVAS 
trial demonstrated that a regimen that rapidly reduces the dose to 20 mg daily by 7 weeks and 
5 mg daily by 19 weeks is as effective and safer than more traditional, higher-dose 
regimens192. Glucocorticoids are the major modifiable cause of adverse events during the 
induction period and lower-dose regimens reduce the risk of severe infections. There is no 
consensus for glucocorticoid dosing in non-severe disease and lower initial doses may be 
used. The RITAZAREM trial demonstrated that patients with relapsing disease respond well 
to lower initial doses, such as 0.5 mg/kg daily, whether or not they had severe disease193. 
Intravenous pulse methylprednisolone (total dose 1–3 g) at the initiation of therapy for severe 





Other immunosuppressive or immunomodulating drugs. The combination of 
glucocorticoids with either cyclophosphamide or rituximab is the current standard of care for 
remission induction in severe disease, although as further evidence supporting the efficacy of 
rituximab emerges, it is becoming the preferred induction agent for many patient subgroups, 
such as children and adults for whom the preservation of fertility is important, PR3-ANCA+ 
patients and in relapsing disease. However, rituximab is more expensive and globally is not 
as available as cyclophosphamide. Cyclophosphamide dosing is either by intermittent 
intravenous pulse treatments or by a daily oral dose. Doses are reduced for increasing age and 
renal impairment; either regimen is usually discontinued after 3–6 months, with subsequent 
initiation of remission maintenance therapy. Close monitoring is essential to minimize the 
risk of myelotoxicity. Intravenous regimens deliver ~50% of the cumulative dose compared 
with daily oral dosing, with similar remission rates, but lower cyclophosphamide exposure is 
associated with a higher subsequent relapse risk194,195. 
 In two randomized trials, rituximab was non-inferior to cyclophosphamide for 
remission induction and, in a post-hoc analysis of the RAVE trial, superior for PR3-ANCA+ 
patients or those with relapsing disease160,196,197. These trials used 375 mg/m2 weekly for a 
total of four doses, although two 1,000 mg doses (two-week interval) are also widely used. 
There is a paucity of comparative data on the use of either cyclophosphamide or rituximab in 
patients with low GFR (for example, <20 ml/min/1.73 m2), with a lower dose of 
cyclophosphamide together with rituximab being used in the RITUXVAS trial198. The use of 
this combination is controversial and may confer an additional risk of infection199. 
 For non-severe disease, alternative immunosuppressive agents to cyclophosphamide, 
such as methotrexate and mycophenolate mofetil, are equivalent to cyclophosphamide in 
terms of remission rates at 6 months but have higher subsequent rates of relapse and greater 
accrual of damage, especially for PR3-ANCA+ disease. Methotrexate has been recommended 
for patients with no threat of organ-damaging disease, although longer term outcomes (such 
as relapse and damage accrual) are worse than with cyclophosphamide200. Such patients are 
uncommon and often require later use of cyclophosphamide or rituximab for control of more 
severe or relapsing disease. The MYCYC trial found similar responses with mycophenolate 
mofetil and cyclophosphamide in for MPO-ANCA+ patients, at both 6 and 18 months201, and 
two other small randomized trials support a role for this agent as an alternative for this 
subgroup. 
Adjunctive therapy. Although smaller studies demonstrate that use of plasma exchange is 




>500 mol/l at diagnosis202, the results of the large PEXIVAS trial indicate that plasma 
exchange should not be routinely recommended for GPA or MPA with nephritis or lung 
haemorrhage192. Whether specific patient subgroups, such as those that are oliguric at 
presentation or with hypoxic respiratory failure, benefit from plasma exchange requires 
further study. In one study, high-dose intravenous immunoglobulin (2 g/kg total dose) 
improved disease control of AAV that was refractory to usual therapy203 and can be 
considered when conventional agents are contraindicated, such as in the setting of severe 
infection. 
 
Therapy to maintain remission 
 The goals of maintenance therapy are to prevent relapse, minimize the risk of 
comorbidities and drug toxicity and manage the consequences of organ damage, such as 
chronic kidney disease. Many patients with AAV require prolonged low-dose glucocorticoids 
(prednisone ≤10 mg daily) to maintain remission, even if also treated with rituximab or an 
oral immunosuppressive drug. 
 In the MAINRITSAN and RITAZAREM trials of interval treatment, rituximab was 
superior to azathioprine193,204. These findings are consistent with previous observational data 
and are driving a revision of guidelines. Azathioprine, methotrexate or mycophenolate 
mofetil, with or without oral glucocorticoids, can be used after cyclophosphamide to maintain 
remission in patients with AAV. The optimal duration for treatment with these agents is 
uncertain, with the REMAIN trial supporting 3–4 years of treatment regardless of ANCA 
subtype or positivity205. The MAINRITSAN trial results indicate that following use of 
cyclophosphamide in patients with new-onset disease, a reduction in relapse rates occurs with 
use of rituximab (500 mg every six months over 2 years) compared with azathioprine. 
MAINRITSAN3 showed that following the initial two years of treatment, a further two years 
of rituximab treatment also reduced relapse rates206. The RITAZAREM trial confirmed and 
extended these observations in a cohort of patients with relapsing disease in whom remission 
was re-induced with rituximab and glucocorticoids, with maintenance rituximab at 1000 mg 
every four months over two years193,207. Both the MAINRITSAN trial results and 
observational data point to an increase in relapse risk after rituximab withdrawal, compared 





 There remains widespread use of oral immunosuppressive drugs after induction of 
remission with cyclophosphamide, at least until first relapse. The use of either CD19 counts 
or serum ANCA levels to guide redosing of rituximab is controversial; a randomized trial 
comparing fixed-interval dosing to biomarker-based dosing showed similar efficacy of these 
dosing regimens and reduced frequency of redosing, but more relapse when based on 
biomarkers209. 
 Several factors alter the risk of relapse in AAV, including disease phenotype (GPA 
relapses more than MPA), ANCA subtype (PR3-ANCA+ patients relapse more than MPO-
ANCA+ patients), a history of previous relapses, the presence of ENT disease, and the 
absence of severe renal disease208. Following induction therapy, persisting or the return of 
ANCA positivity, S. aureus infection and lower cyclophosphamide exposure are linked to 
increased risk of relapse, but confirmation of these findings and testing in a clinical trial 
setting are needed prior to routine application to practice. As withdrawal of therapy seems to 
increase risk of relapse, patient-level factors to consider around drug withdrawal are the 
likely consequences of relapse (for example, end-stage kidney disease in a patient with 
chronic kidney disease), adherence to monitoring, access to expert advice and patients’ views 
on the risks of relapse and ongoing drug exposure. 
 
Treatment of relapses of GPA and MPA 
 Continued regular monitoring of patients with AAV after induction of remission 
enables early detection of relapses with less advanced symptomatology than at presentation 
and reduced delay. When a patient is considered to be having a relapse, a review of the 
primary diagnosis and vasculitis mimics, such as infection, malignancy or recreational drug 
use, should be excluded. Non-adherence to prescribed medications is also often a concern. 
One-third of relapses are severe, with consequences for renal and patient survival. Treatment 
of relapse follows the same principles as for initial therapy, but rituximab is preferred in view 
of superior responses in the RAVE trial in relapsing patients and the beneficial effects seen in 
the RITAZAREM trial193,196,197. 
 
Treatment of refractory disease 
 Refractory disease in AAV has been defined as a failure to achieve full control of the 
vasculitis-related disease activity by six months, progressive disease within the first three 
months or relapse despite adequate ongoing therapy for maintenance of remission. It is 




caused by disease damage or mimics of vasculitis, which is most relevant in respiratory tract 
disease, for which comprehensive assessment and treatment of any infection should 
accompany the evaluation of the vasculitis. An increase in glucocorticoid dose, such as the 
use of intravenous methylprednisolone, is used in severe disease relapse but prolonged use of 
high-dose oral glucocorticoids should be avoided due to the associated risks. Switching from 
cyclophosphamide to rituximab can be considered. Adjunctive therapies to consider are 
plasma exchange or intravenous immunoglobin (discussed above). 
 
Treatment of EGPA 
 The approach to treat patients with EGPA with severe disease is similar to that in 
GPA and MPA (Table 4). Treatment strategies for EGPA vary according to disease 
manifestations and severity, and concomitant manifestations of asthma should be managed 
assertively. The FFS is used to stratify patients with EGPA, and the presence of substantial 
renal involvement (severe proteinuria or impaired kidney function), cardiomyopathy, 
gastrointestinal involvement or central nervous system involvement indicates a need for more 
intensive treatment, such as a cyclophosphamide and glucocorticoid regimen analogous to 
that used in GPA and MPA. Although one trial failed to demonstrate a benefit of oral 
immunosuppressive drugs in non-severe disease210, these agents are widely used in an 
attempt to reduce the high glucocorticoid requirement typical for this disease. The anti-IL-5 
monoclonal antibody mepolizumab is a further therapeutic option that has demonstrated 
effects on airways and allergic manifestations143. In a randomized clinical trial, mepolizumab 
was useful in most patients, especially for asthma and sinonasal disease, by maintaining 
sustained remission, reducing relapse rates or substantially reducing the dosage or duration of 
glucocorticoid therapy211. Rituximab can also be used in EGPA, but its efficacy is less well 
established than for GPA and MPA, particularly for ANCA– patients with EGPA, who show 
frequent relapse of asthma and sinonasal disease despite continued use of rituximab212. 
 
Monitoring disease activity 
 Clinical assessment and investigation follow the goals of maintenance outlined above, 
namely early identification of return of disease activity, screening for drug toxicity and 
management and recognition of comorbidities. Serum creatinine measurement and urine 
analysis to detect haematuria and proteinuria should be undertaken regularly to assess disease 
activity and kidney function. Additional elements include patient education and psychosocial 




after rituximab treatment. IgG levels should be checked periodically after treatment and 
falling levels should influence the decision on repeat dosing. Routine CD19 counts (a 
measure of B cell levels) are not required but may be informative in patients with incomplete 
response to rituximab or early relapse. Microbiological assessment of the nasopharynx and 
infection control with topical antiseptic agents or antibiotics may improve symptomatic 
management. More intensive monitoring may be required for organ-specific issues, such as 
bronchoscopy in tracheo-bronchial disease, repeat renal biopsy in advanced renal impairment 
with persisting urinary abnormalities, and cardiac imaging (echocardiography and MRI) in 
cases of cardiac involvement  
 
Comorbidities and treatment effects  
 Infection is the most frequent serious problem in the first year of AAV treatment. 
Routine prophylaxis against Pneumocystis jirovecii pneumonia with sulfamethoxazole–
trimethoprim (or alternative agents) is recommended andmay also reduce the frequency of 
other bacterial infections. Independent of its value in Pneumocystis jirovecii prophylaxis, 
there is not enough evidence to recommend routine use of long-term sulfamethoxazole–
trimethoprim in PR3-ANCA+ patients to prevent disease relapse. Avoidance of severe drug-
induced leukopenia is crucial. Rituximab-induced immunodeficiency and any case of 
recurrent infection requires further immunological assessment. Cases of 
hypoimmunoglobulinaemia with frequent infections may prompt use of replacement 
immunoglobulin213. Routine vaccination against influenza and pneumococcal infection is 
recommended for all patients, although serological responses may be impaired, especially 
following rituximab treatment. 
 Venous thromboembolism should be treated with anti-coagulation agents, although 
these can be problematic in the setting of pulmonary haemorrhage214. The risk of 
cardiovascular events is markedly raised in patients with more extensive disease, those 
without PR3-ANCA, and in the presence of renal impairment174,215. There is no current 
advice concerning reducing these risks that is specific to patients with AAV, although careful 
attention to management of hypertension and hyperlipidaemia is recommended. 
 Cyclophosphamide and other oral immunosuppressive drugs are associated with an 
increased risk of malignancies, particularly non-melanoma skin cancer and urothelial 
malignancy216,217. The rates of these cancers are falling with reduced immunosuppressant 
exposure, especially to cyclophosphamide, and the increased use of rituximab218. The relative 




malignancy in patients exposed to cyclophosphamide should be lifelong. Prophylaxis against 
gastric toxicity is often prescribed with high-dose glucocorticoids, which also increase the 
risk of osteoporosis219. 
 The management of organ damage in patients with AAV requires sub-specialist 
intervention by those with appropriate experience, in co-ordination with the primary physician 
overseeing the AAV treatment. Examples include surgical correction of lacrimal duct 
obstruction, middle ear disease, nasal collapse and subglottic or endobronchial stenosis220. Renal 
transplantation is generally successful in patients with AAV, although opportunistic infections 
may be more common than in transplant recipients without AAV, reflecting the prior burden of 
immunosuppressive therapy for AAV. Recurrence of vasculitis in the renal graft occurs in 2% of 
transplant recipients with AAV and can lead to graft failure. Long-term patient survival is 




Quality of Life 
 Patients are well aware of the challenges they face in managing AAV and self-report 
substantial effects on QOL from AAV itself as well as the burden of treatment and treatment-
related toxicities (Box 4). The evolution in immunotherapeutics has transformed AAV into a 
chronic disease and in consequence, patient priorities have realigned. Rather than focus on the 
spectre of major organ damage, patients rank QOL domains, such as fatigue and pain, as the 
greatest disease priorities222. 
 There can be key differences between patient and clinician perceptions of these priorities. 
For example, although patients and clinicians both rank weight gain as a major concern about 
glucocorticoid treatment, patients frequently cite ‘moon face’ and other effects on appearance as 
highly concerning, whereas clinicians tend to not consider these effects to be as important as the 
risk of infection. A closer assessment of patient-reported QOL will provide an opportunity for 
better alignment of patient and clinician priorities. 
 Characterization of a national cohort indicated that patients with AAV experienced 
substantially poorer levels of physical and mental QOL compared with matched controls in the 
general population (physical QOL: OR 7.0, 95% CI 4.4–11.1; mental QOL: OR 2.5, 95% CI 
1.7–3.6), even though the vast majority (80%) of patients had achieved disease remission5. 
 Modern induction agents certainly result in noticeable improvements in QOL, but gains 
are modest and patient QOL rarely returns to normal levels196. Several factors may explain this 
situation. First, high-dose glucocorticoids remain integral to standard care but they have multiple 
toxic effects, including on QOL domains such as mental health223, which should be assessed 
using, for example, the Glucocorticoid Toxicity Index224. Second, almost all studies of QOL in 
patients with AAV have used generic questionnaires, such as the 36-item Short Form Health 
Survey (SF-36), the EuroQol-5 Dimension (EQ-5D) and the Health Assessment Questionnaire, 
which may not capture AAV-specific issues.  
The OMERACT Vasculitis Working Group developed a 29-item patient-reported 
outcome (PRO) tool, the AAV-PRO questionnaire225,226, which covers six domains (organ-
specific symptoms, systemic symptoms, treatment adverse effects, social and emotional effect, 
concerns about the future and physical function), following patient qualitative interviews to 
address this unmet need. The AAV-PRO is being integrated into ongoing randomized controlled 
trials. Similarly, the Patient-Reported Outcomes Measurement Information System (PROMIS) 
covers fatigue, physical functioning and pain interference. Both PRO systems assess function 
and QOL, are complementary and require further validation, but they offer options to ensure 




Impairments in QOL are the result of multiple factors, not only active inflammatory 
disease but also disease damage, although they seem to be primarily related to psychosocial 
factors, such as fatigue and dysfunctional coping strategies5 and skeletal dysfunction. 
Persistently high levels of fatigue that does not change after treatment occurred in some patients 
in a SF-36 vitality domain sub-analysis of the MYCYC and RITUXIVAS studies227. 
Furthermore, there were marked disparities in physical QOL, including reduced knee extension 
(76%), among patients with AAV compared with healthy controls. This reduced knee extension 
was associated with impaired SF-36 Physical Component Score, as were metrics of pre-existing 
muscle strength228. 
 As QOL differs for each patient, measuring QOL can also be helpful in developing more 
personalized treatment approaches. Studies examining whether physical activity improves 
fatigue in patients with AAV are underway229. As disease assessment in AAV should include 
function or QOL168, reliable PRO tools are crucial not only for monitoring individual patients 






 Substantial progress has been made in understanding and treating AAVs. GPA, MPA and 
EGPA have gone from diseases with a high mortality within 1–2 years of the onset of symptoms 
to chronic conditions that require lifelong specialist management. However, major challenges 
remain. AAVs are still responsible for substantial morbidity and mortality, both from the 
diseases themselves and from their treatments. Most treatments are fairly non-specific and come 
with undesirable immune and metabolic adverse effects. Furthermore, the optimal duration of 
therapy is uncertain, in part because of a lack of reliable predictors of relapse. More effective 
management of AAV in the future will rely on a better understanding of the clinical aspects of 
the disease and of disease-causing processes, together with the development of effective 
biomarkers to better define disease activity and predict relapse. More precise, effective and less 
toxic treatments require better knowledge, continued recognition of unmet clinical need, and 
additional strategic and successful well-designed international collaborative clinical trials. These 
efforts must be combined with more explicit recognition of important patient-centred outcomes, 
both in trials and in clinical practice. EGPA, as an even less common form of AAV with 
different clinical features to GPA and MPA, poses great challenges. In EGPA, even more than in 
GPA and MPA, multidisciplinary and international collaborations are required to improve the 
QOL of people with this disease. Table 5 summarizes some of the emerging therapies and 
biomarkers in AAV. 
 Better diagnostic and classification criteria of AAV will assist understanding, clinical 
studies and improvements in patient care. The near-complete DCVAS study has developed 
data-driven classification criteria for systemic vasculitides and should provide improved 
standardized criteria. Furthermore, whereas EGPA is clearly a distinct disease entity, for 
GPA and MPA the relationships and overlap between the syndromic classifications (GPA and 
MPA) and the presence of autoreactivity to either PR3 or MPO (PR3-ANCA+ or MPO-
ANCA+) must be more clearly understood to aid progress in understanding, in clinical trial 
design and in management strategies. These efforts are not only important for improved 
induction therapies, but also for defining treatment duration and the management of relapse. 
 Epidemiologically, there is inadequate data pertaining to EGPA in general, as well as a 
clear need to define the occurrence of all AAV types in Africa and South Asia. A better 
definition of the nature and burden of disease is likely to improve clinical care and outcomes, 
while more detailed understanding of the epidemiological associations will inform disease 
pathogenesis. The recognition that AAV is an autoimmune condition and the role of ANCAs in 




inadequacies of current therapies demand a more detailed understanding of pathogenesis. Many 
questions remain. Can elucidating genetic contributions to AAV pathogenesis, including that of 
EGPA, lead to pathway-directed therapies, either with new therapies or by repurposing existing 
therapeutics? Why are only some ANCAs pathogenic, and if we understand this, can we 
measure specific ANCA subtypes to develop more effective biomarkers? As there is substantial 
deposition of ANCA antigens in affected tissues, why is immunoglobulin deposition not more 
prominent? Why are some organs and tissues preferentially affected? Why do some individuals 
lose tolerance to PR3 or MPO, whereas most do not, when these neutrophil proteins are 
frequently released in an immunologically ‘dangerous’ infectious and inflammatory context? 
Can immunological tolerance be re-established by antigen-specific immunomodulation? 
Although much is known about events in the acute effector phase of injury, key events in more 
chronic disease and the role of T and B cell memory are unclear. Better understanding of these 
issues has the potential to move the goalposts in developing treatments that induce long lasting 
remission and tolerance. 
 Key uncertainties in the care of patients with AAV include the optimal duration and 
intensity of maintenance therapy in an individual patient, and a lack of biomarkers that signal 
relapses. Better biomarkers, either singly or in combination, to predict severity and relapse risk 
would lead to a more precise treatment approach. Emerging biomarkers include urinary sCD163, 
which could be useful in determining renal relapse, with or without other markers165,230. 
Following from observations that relapse risk in patients with AAV is associated with an ‘active’ 
T cell signature (that is, reduced expression of genes related to T cell exhaustion)136, prospective 
clinical trials are underway to determine whether markers of this signature can inform treatment 
intensity. Other potential biomarkers are emerging and are undergoing further evaluation166. 
 The potential for complement inhibition (by targeting C5aR) is one of several therapeutic 
strategies aimed at limiting neutrophil activation. Complement inhibition therapies could reduce 
or replace the current reliance on glucocorticoids in induction therapy regimens, as in phase II 
and III trials of C5aR inhibition110,111. Glucocorticoids are a pillar of maintenance therapy for 
many patients and this reliance needs to be mitigated. In EGPA, further clinical trials in IL-5–IL-
5R blockade will hopefully improve therapeutic options in this disease. Much attention has 
justifiably been given to ANCA–neutrophil-mediated events in AAV but the more selective 
inhibition of the underpinning T and B cell autoimmunity also has potential in inducing and 
maintaining remission. The goal in the treatment of AAV is not only to supress disease, but also 
to restore tolerance. Currently, there are no clear markers of tolerance to reassure clinicians and 




new tolerogenic, curative therapies. Whereas tolerogenic strategies that have been applied to 
other diseases might be suitable for AAV, outcome measures in AAV are unclear, although at 
least in the case of MPO as an autoantigen, progress has been made in defining key epitopes. 
 A multidisciplinary approach and patient engagement would result in a more integrated 
treatment strategy and improved outcomes in these complex multisystem diseases. Clinicians 
and patients should work together in a clinical setting to increase involvement of patients in their 
own care and treatment decisions. There are several dimensions to this issue. The educational 
needs of patients newly diagnosed with AAV are high, and the rarity of the conditions makes 
meeting these needs complicated. In the clinical trial environment, the use of PRO measures, 
such as AAV-PRO, should be mandatory. Interventional trials that include outcome measures 
that focus on improving physical and mental QOL are just beginning229. AAVs are challenging 
and complex conditions but, with an integrated, collaborative approach that includes 
considerable patient involvement, great progress can be made in improving the lives of people 
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Table 1. Comparison of the three syndromic presentations of AAV  
 
GPA MPA Eosinophilic GPA 
Incidence 0.4–11.9 cases per 1 
million person-years 
0.5–24.0 cases per 1 
million person-years 
0.5–2.3 cases per 1 million 
person-years 
Prevalence 2.3–146.0 cases per 1 
million persons 
9.0–94.0 cases per 1 
million persons 





45–65 55–75 38–54 
Male: 
female 







involving the upper and 




(such as capillaries, 
venules, arterioles, arteries 
and veins). Necrotizing 
glomerulonephritis is 
common. 
Necrotizing vasculitis, with 
few or no immune 
deposits, predominantly 
affecting small vessels 
(such as capillaries, 
venules, or arterioles). 
Necrotizing arteritis 
involving small and 
medium arteries may be 
present. Necrotizing 
glomerulonephritis is very 
common. Pulmonary 
capillaritis often occurs. 
Granulomatous 




involving the respiratory 
tract; necrotizing vasculitis 
predominantly affecting 
small-to-medium vessels; 
associated with asthma and 
eosinophilia. ANCA+ is 

















Neutrophil Neutrophil Eosinophil 
Relapse 
rate 
Higher than MPA (or 
MPO-AAV) 
Lower than GPA (or 
PR3-AAV) 
Relapse is frequent 
 
= AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic antibody; CHCC, 
Chapel Hill Consensus Conference; GPA, granulomatosis with polyangiitis; MPA, 




Table 2. Key clinical trials of induction therapies for GPA and/or MPA  
Name Population Intervention Key result Other findings Refs 
Induction therapy  
CYCLOPS Newly diagnosed 
GPA or MPA, renal 
involvement, ANCA+a 
or ANCA– if biopsy 
IV versus oral CYC, plus 
GCs 
IV non-inferior to oral 
CYC in inducing 
remission; ~50% 
cumulative dose with IV 
versus oral CYC 
Decreased relapse with 
oral CYC (HR 0.50) at 
long-term follow up 
194,195 
CORTAGE New diagnosis, age 
≥65 yearsb 
IV-CYC (maximum 6 x 
500 mg, every 2–3 weeks) 
plus 9 months GCs versus 
IV CYC (~5.5g) plus 26 
months GCs  
Similar remission rates  Fewer serious adverse 
events with lower dose 
CYC and GCs  
231 
RAVE GPA or MPA newly 
diagnosed or 
relapsing, ANCA+, 
SCr <353 mol/l 
RTX versus oral CYC, 
then AZA 
RTX non-inferior to 
CYC. RTX may be 
better for relapsing 
AAV 
Similar short-term adverse 
effects, similar relapse 
rates with single-dose 
RTX 
196,197 
RITUVAS GPA or MPA newly 
diagnosed, renal 
involvement, ANCA+ 
2 doses IV-CYC, then 
RTX versus IV-CYC 




MEPEX GPA or MPA with 
biopsy proven 
glomerulonephritis, 
SCr >500 mol/l, 
ANCA+ or ANCA– 
PLEX versus IV-MP as 
add-on to CYC and GCs 
PLEX superior in rates 
of dialysis independence 
at 3 months and renal 







GPA or MPA newly 
diagnosed or relapsing 
with renal 
involvement (eGFR 
<50 ml/min/1.73 m2) 
or pulmonary 
haemorrhage, ANCA+ 
a) PLEX as add on to 
CYC or RTX and GCs 
b) Low-dose GCs versus 
high-dose GCs, 
plus RTX or CYC 
a) PLEX not superior 
b) low-dose GCs non-
inferior, with fewer 
serious infections 
Effects similar across 
subgroups 
192 
CLEAR Phase II, newly 
diagnosed or relapsing 
GPA or MPA with 
renal involvement, 
ANCA+ 
Avacopan and reduced 
GCs or no GCs, versus 
GCs, plus RTX or CYC 
Avacopan not inferior Avacopan: faster reduction 
in proteinuria, better QOL 
indices with no GCs 
110 
ADVOCATE Phase III, newly 
diagnosed or relapsing 
GPA or MPA, 
ANCA+ 
Avacopan versus GCs, 
plus RTX or CYC then 
AZA 
Avacopan non inferior 
to GCs, superior for 
sustained remission at 
one year 




IVIg Active GPA or MPA, 
>2 months CYC and 
GCs, ANCA+ 
CYC and GCs versus add-
on IV-Ig (single dose 2 
g/kg)  
Response: 14/17 IV-Ig, 
6/17 placebo 
Effects did not extend 
beyond 3 months 
203 
NORAM Newly diagnosed 
GPA or MPA, less 
severe disease  
MTX (20–25 mg weekly) 
versus oral CYC 
MTX non-inferior for 
remission induction 
MTX less effective for 
extensive or pulmonary 
disease; relapse more 
frequent with MTX  
200,235 
MYCYC New diagnosis of 
GPA or MPA, eGFR 
>15 ml/min/1.73 m2 
IV-CYC versus MMF (2–
3 g daily) 
MMF non-inferior for 
remission induction 





a ANCA+ refers to a positive test at any time, not ANCA+ at the time of entry into study. 
b Study also included polyarteritis nodosa (10 patients) and eosinophilic GPA (14 patients), of the 104 patients. 
AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic antibody; AZA, azathioprine; CYC, cyclophosphamide; eGFR, estimated 
glomerular filtration rate; GCs, glucocorticoids; GPA, granulomatosis with polyangiitisHR, hazard ratio; MMF, mycophenolate mofetil; MPA, 





Table 3. Key clinical trials of therapies to maintain remission in GPA and/or MPA 
Maintenance therapy 
CYCAZAREM New diagnosis GPA or MPA, 
SCr <500 mol/l, ANCA+ or 
ANCA– if biopsy 
Induction oral-CYC or 
GCs 3–6 months (to 
remission), then CYC 
1.5mg/kg daily versus 
AZA to 12 months 
Similar relapse rates Relapse more common 
in GPA than MPA 
236 
WEGENT GPA or MPA in remission, 
initially treated with IV CYC 
and GCs, ANCA+ or ANCA– 
if biopsy  





IMPROVE GPA or MPA newly 
diagnosed, in remission, 
ANCA+ 
MMF versus AZA Relapse more common 
with MMF (HR 1.69) 
Similar adverse event 
rates 
239 
REMAIN GPA or MPA in remission 18–
24 months post diagnosis, 
ANCA+ or ANCA– with 
biopsy 
AZA or GCs for 48 
months versus withdrawal 
by 24 months 
Relapse higher with 
withdrawal (OR 5.96) 
More serious adverse 
events in continuation 
group 
205 
MAINRITSAN GPA or MPA in remission 
after CYC and GCs, ANCA+ 
RTX (500 mg, every six 
months) versus AZA 
Relapse higher with 
AZA at 28 months 
(HR 6.61) 
Similar rates of 
adverse events 





at long-term follow up 
MAINRITSAN2 GPA or MPA, in remission, 
ANCA+ and ANCA- 
Scheduled RTX versus 
RTX tailored to B cell 
return and/or ANCA 
No difference in 
relapse rates 




MAINRITSAN3 GPA or MPA, sustained 
remission, 2 years after RTX 
maintenance therapy 
No additional treatment 
(placebo) versus 2 further 
years of RTX  
Relapse higher with 
placebo: 26% versus 
4% (HR 7.5) 
No increase in adverse 
events with extended 
RTX 
206 
RITAZAREM Relapsed GPA or MPA re-
induced with RTX and GCs, in 
remission, ANCA+ 
RTX (1 g every 4 months) 
versus AZA 
RTX superior in 
preventing relapse (HR 
0.36) 
No increase in adverse 
events with RTX  
193,207 
WGET GPA with active disease, 
ANCA+ or ANCA– 
Standard therapya (pre-
RTX era) versus add-on 
etanercept (TNF inhibitor) 




solid organ tumours 
241 
Metzler et al.  GPA, complete or partial 
remission 
LEF versus MTX Relapses: MTX 13/28, 
LEF 6/26 patients 
LEF: 19% withdrawal 
with adverse effects at 
30 mg dose 
242 
BREVAS GPA or MPA in remission 26 
weeks after induction, ANCA+ 
AZA and low-dose GCs 
versus add-on belimumab 
No improvement with 
belimumab, but low 
relapse rate in placebo 
group 
Recruitment lower 
than planned due to 
change in clinical 
practice 
243 










a Several treatment pathways were available, depending on the severity and activity of disease and other factors, but usually involved either MTX 
plus GCs, then taper and try to cease GCs; or oral CYC and GCs, then MTX or AZA taper and try to cease GCs. 
AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic antibody; AZA, azathioprine; CYC, cyclophosphamide; GCs, 
glucocorticoids; GPA, granulomatosis with polyangiitis; HR, hazard ratio; LEF, leflunomide; MMF, mycophenolate mofetil; MPA, microscopic 





Table 4. Key clinical trials of therapies for EGPA  
 
Trial Population Intervention (n) Key result Other findings Refs 
Ribi et al.  Treatment failure or 
relapse on GCs alone, 
limited disease, 1996 
FFS = 0 
GCs and IV-CYC (10) 
versus GCs and AZA (9)  
No significant 
differences in remission; 
CYC 5/10, AZA 7/9 
Most remained on GCs 245 
Puéchal et al.  New diagnosis, limited 
disease, 1996 FFS = 0, 
included other AAV 
GCs (25) versus add-on 
AZA (26)  
No effect on combined 
endpoint of remission 
induction and relapse 
No change in exacerbations 
of asthma/rhinosinusitis. 
Long-term outcomes similar 
210,246 
MIRRA Relapsing or refractory 
EGPA, stable GC dose 
(7.5–50 mg) 
GCs (68) versus add-on 
SC-mepolizumab every 
four weeks for 52 weeks 
(68)  
Mepolizumab effective, 
mainly in allergy related 
manifestations 
Post hoc analysis suggests 
>75% of patients derived 
benefit 
143,211 
Guillevin et al.  Non-severe EGPA 
(included PAN) 
GCs versus add-on 
PLEX (18 in total)  
No benefit, results 
grouped together with 
patients with PAN 
Reflects historical grouping 
of disease 
247 
Guillevin et al.  Severe EGPA (included 
PAN) 
IV-CYC and GCs (6) 
versus add-on PLEX (8)  
No benefit, results 
grouped together with 
patients with PAN 







AAV, ANCA-associated vasculitis; AZA, azathioprine; CYC, cyclophosphamide; EGPA, eosinophilic granulomatosis with polyangiitis; FFS, Five 





Table 5. Selected potential new management strategies and biomarkers in AAVa 
 Potential strategy Stage of development 
Treatments   
Complement inhibition Avacopan (small-molecule C5aR antagonist)110 Phase III trial completed (NCT02994927)111 
SYK inhibition Small-molecule inhibitors249 Pre-clinical model proof-of-concept studies (MPO-
AAV) 
Eosinophils and TH2 cells in 
EGPA 
Direct or indirect targeting of eosinophils and 
TH2 cells
b, for example anti-IL-5R 
(benralizumab), TH2 cell and eosinophil 
chemokines 
Non-inferiority clinical trial comparing mepolizumab 
with benralizumab (NCT04157348) 
BAFF inhibition Belilumab243 as add-on to rituximab Phase II trial in progress (NCT03967925) 
Co-stimulatory signal blockade  Abatacept250 Phase II trial in progress (NCT02108860) 
T cell or TH cell-defining 
cytokine inhibition 
Monoclonal antibodies, for example 
ustekinumab (anti-IL-12p40)121,218  
Pre-clinical model proof-of-concept studies 
published (MPO-AAV)121,251 
Tolerogenic therapies Peptide and antigen tolerogenic platforms Pre-clinical model proof-of-concept studies 
published252 (MPO-AAV) 
Biomarkers   
Renal activity or flare Urinary soluble CD163 with or without other 
biomarkers (for example, soluble CD25 and 
CCL2)165,230  
Further clinical studies for biomarker utility 
Overall risk of flare Markers of T cell activity and exhaustion in 
AAV135,136  
Trials of 17-gene qPCR stratification for prognosis in 
other diseases 144 




aOnly those for which a rationale has been established are included. 
bIn addition to anti-IL-5 strategies already in clinical use. 
AAV, ANCA-associated vasculitis; BAFF, B cell-activating factor; EGPA, eosinophilic granulomatosis with polyangiitis; MPO, myeloperoxidase; 









Figure 1. Small vessel vasculitis. a | The updated 2012 Chapel Hill Consensus Conference 
classification of vasculitis145, which is based on the size of the main vessels that are affected. 
The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides, namely 
granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic 
granulomatosis with polyangiitis (EGPA), are small vessel vasculitides. b | Patterns of ANCA 
staining by indirect immunofluorescence. A cytoplasmic pattern of staining for ANCA 
(cANCA) is strongly associated with antibodies against PR3. A perinuclear pattern of staining 
for ANCA (pANCA) is seen with antibodies against several different proteins, but anti-MPO 
antibodies are most relevant for AAV. Scale bar = 10 m. Part a adapted with permission from 











Figure 2. Global epidemiology of ANCA-associated vasculitides. The map depicts studies that 
have examined the incidence of granulomatosis with polyangiitis (GPA) and microscopic 
polyangiitis (MPA) per 1 million individuals per year. There is substantial variation in the 
relative incidences of GPA and MPA between Europe and Asia, and an effect of latitude. The 
regions studied include Australia254; Canada255; Germany256; Greece257; Japan258; Lithuania259, 
Turkey260; Peru261; Spain (Lugo)262; Spain (Malaga)263; Sweden264; the United Kingdom18; the 












Figure 3. Pathogenetic events in GPA and MPA. Simplified schematic showing events 
leading to acute tissue injury in two forms of anti-neutrophil cytoplasmic antibody (ANCA)-
associated vasculitis (AAV), namely granulomatosis with polyangiitis (GPA) and microscopic 
polyangiitis (MPA). Risk factors for loss of tolerance and disease (olive) include genetic and 
environmental factors, age and infection or inflammation. These AAVs involve autoreactive 
elements (blue-green), including effector cell responses to the neutrophil proteins leukocyte 
proteinase 3 (PR3) and myeloperoxidase (MPO) by autoreactive T cells and B cells, with the 
humoral response resulting in the production of ANCAs. The key steps in the effector phase 
(yellow) are neutrophil priming and activation by ANCA with subsequent neutrophil localization 
to the microvasculature and injury. MPO and PR3 are deposited in and around the 
microvasculature of target tissues and effector T cells recognize these antigens, resulting in pro-
inflammatory cytokine production and further recruitment of effector leukocytes. These 
responses lead to tissue injury and endothelial damage (orange). Less is known about the 








Figure 4. Loss of tolerance and the generation of effector responses in GPA and MPA. 
Genetic risk factors in an ageing host combine with known or unknown environmental factors 
(possibly including silica, certain medications or drugs) and potentially infection to induce a loss 
of T and B cell tolerance to one of two clinically recognized neutrophil antigens, leukocyte 
proteinase 3 (PR3) or myeloperoxidase (MPO). Autoantigen-specific T cells become activated 
and differentiate into T helper (TH) cells, including T follicular helper (TFH) cells that provide 
help to B cells, type 1 T helper (TH1) cells and IL-17A-producing T helper (TH17) cells; an 
exhausted phenotype is associated with reduced risk of disease relapse. B cells differentiate into 
plasma cells and memory cells. Plasma cells secrete autoantibodies against PR3 (PR3-ANCA) or 
MPO-ANCA. Neutrophils are activated and primed by pro-inflammatory cytokines, pathogen-
associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) 
engagement with Toll-like receptors (TLRs), and binding of C5a to the C5a receptor on 
neutrophils. ANCAs bind to neutrophils in an antigen-specific manner and to neutrophils and 
monocytes in a Fc receptor (FcR)-dependent fashion. AAV, ANCA-associated vasculitis; 
BAFF, B cell-activating factor; Breg cells, regulatory B cells; GPA, granulomatosis with 
polyangiitis; MHC-II, major histocompatibility class II; IFNγ, interferon-γ; MPA, microscopic 
polyangiitis; NET, neutrophil extracellular trap; TNF, tumour necrosis factor; Treg cells, 






Figure 5. Endothelial and tissue injury in GPA and MPA. Anti-neutrophil cytoplasmic 
antibody (ANCA)-activated, primed neutrophils localize to the endothelial cells in the 
microvasculature of the kidneys, respiratory tract and other tissues. Recruitment is mediated by 
adhesion molecules and chemokines. Adherent neutrophils induce endothelial injury by several 
mechanisms. They produce reactive oxygen species (ROS) and degranulate, releasing proteases 
and ANCA antigens. They generate neutrophil extracellular traps (NETs) and undergo cell death 
by NETosis. ANCA antigens released by neutrophils, and when in a complex with major 
histocompatibility complex class II (MHC-II) or MHC-I, can be recognized as antigenic peptides 
by effector T helper 1 (TH1) cells, IL-17 producing T helper (TH17) cells and CD8
+ T cells, at 
least in the case of myeloperoxidase (MPO). Antigen-presenting cells can include endothelial 
cells, intravascular monocytes and dendritic cells (DCs). Cytotoxic CD4+ T cells expressing 
NKG2D recognize MHC-I-polypeptide-related sequence A (MICA), which is upregulated on 
activated endothelial cells and in granulomas. Mechanisms of extravascular tissue injury include 
the extravasation of inflammatory leukocytes and the formation of B cell aggregates that may 
present ANCA antigens to T cells, produce pro-inflammatory cytokines and produce ANCA in 
situ. Tissue-resident and recruited DCs present antigen, whereas tissue-resident and recruited 
macrophages are pro-inflammatory and pro-fibrotic. These macrophages shed soluble CD163 
(sCD163), which is a potential biomarker of disease activity. Leukocytes within granulomas 
contribute to inflammatory injury. Ag, antigen; DAMPs, damage-associated molecular patterns; 
FcR, Fc receptor; ICAM1, intercellular adhesion molecule 1; IFNγ, interferon-γ; PAMPs, 
pathogen-associated molecular patterns; ROS, reactive oxygen species; TCR, T cell receptor; 
TLR, Toll-like receptor; VCAM1, vascular cell adhesion protein 1. 






Figure 6. Clinical features of AAV. a | Schematic showing the organs, organ systems and 
tissues that are affected in the anti-neutrophil cytoplasmic antibody (ANCA)-associated 
vasculitides (AAVs) granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) 
and eosinophilic GPA (EGPA). The approximate relative frequency of involvement is also 
shown. b | Radiological features of sinonasal disease in AAV. Coronal CT images (left) showing 
destruction of the nasal septum, inferior turbinates and right middle turbinate (arrows) in a 
patient with newly diagnosed GPA. Chronic changes in sinonasal GPA (right) showing 
simultaneous nasal septum destruction (white arrow) and neo-osteogenesis (black arrow). c | 
Radiological features of pulmonary hemorrhage in acute AAV. Chest X-ray (left) showing 
infiltrates and changes consistent with acute pulmonary haemorrhage. Transverse CT image 
(right) showing acute pulmonary haemorrhage and ‘ground-glass’ changes (*). =, rate of 
involvement approximately equal to; <, rate of involvement more frequent than; <<, rate of 
involvement substantially more frequent than. aFor EGPA, asthma and allergic manifestations 
are included in the frequency of involvement. Parts b and c courtesy of Prof Kenneth Lau and 





Figure 7. Histopathology of AAV. a | Fibrinoid vessel wall necrosis (N) is the hallmark of 
ANCA-associated vasculitis (AAV), accompanied by a ‘granuloma-like’ mixed inflammatory 
infiltrate (circled) composed of macrophages, lymphocytes, plasma cells and granulocytes in 
microscopic polyangiitis (MPA). b | Resolution of inflammation leads to transmural (arrow) 
fibrous scars (F) and substantial narrowing (*) or even complete occlusion of the vessel lumen. 
c | ‘Geographic’ necrosis (N) of confluent epithelioid granulomas in the lungs in granulomatosis 
with polyangiitis (GPA). Inset shows a subepithelial nasal granuloma in GPA, composed of loose 
aggregates of epitheloid cells and giant cells. d | Epithelioid granulomas (circled) in eosinophilic 
GPA (EGPA) in the nose are more compact and are surrounded by eosinophils. e | Early lesions 
in the lung in MPA often only show neutrophilic capillaritis (C) and fibrinous exudates (*). f | 
Giant cells with sometimes ‘smudged’ appearing nuclei (arrow), neutrophilic granulocytes and 
nuclear debris (*) from neutrophils in epithelioid granulomas in the lungs in GPA. g | Necrosis of 
glomerular capillaries (N) is seen adjacent to an unaffected glomerulus (G) in MPA. h | Lesions 
of different age are seen with partial or circumferential crescents and variable destruction of the 
Bowman capsule (arrowhead) in MPA. i | Neutrophilic capillaritis (C) and multinucleated giant 
cells (GC) are characteristic features of GPA in the nasal mucosa. Staining methods are 
haematoxylin and eosin (parts a–f), acid fuchsin orange G (part g), Periodic acid–Schiff (part h) 







Figure 8. Management of GPA and MPA cases that present with organ or life-threatening 
manifestations. a | Current treatment approaches include an induction phase to induce 
remission, followed by a maintenance phase, then long-term follow up. b | Current induction 
treatment regimens for several diseases are centred on glucocorticoids (GCs), in combination 
with either cyclophosphamide (CYC) or rituximab (RTX). Intravenous GCs are often 
administered after treatment with high-dose oral prednisolone (or prednisone) at an initial dose 
of 50–75 mg. GC dose is tapered over several months, with the standard of care being the 
quicker taper used in the PEXIVAS trial192. The optimal duration of GC therapy in the 
maintenance phase of AAV is unclear, but GCs are often withdrawn over 4–36 months. CYC is 
recommended for induction, for between 3–6 months, and can be administered by intravenous 
pulse or daily oral therapy, with a switch to maintenance therapy at remission (3–6 months). 
Rituximab can also be given for induction therapy in 2–4 doses and is increasingly being used in 
preference to CYC. RTX is given for maintenance therapy, after induction with RTX or CYC. 
Oral immunosuppressive agents, including azathioprine (AZA), methotrexate (MTX) or 
mycophenolate mofetil (MMF), are alternatives for RTX for maintenance therapy. MTX or 
MMF are alternatives to CYC or RTX for induction therapy in non-organ threatening disease. c | 
Disease state corresponding with phase of therapy in parts a and b. Some patients do not respond 
to one of the standard induction regiments and develop refractory disease, whereas others 
relapse while on or after maintenance therapy is halted, and therefore require re-initiation of 




Box 1. Diagnostic testing methods in AAV 
 Most cases of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis 
(MPA) are characterized by anti-neutrophil cytoplasmic antibodies (ANCAs) directed against 
either leukocyte proteinase 3 (PR3) or myeloperoxidase (MPO). In clinical practice, these 
antibodies are detected using indirect immunofluorescence (IIF) and various antigen-specific 
immunoassays, most commonly enzyme-linked immunosorbent assays (ELISAs) for either PR3-
ANCA or MPO-ANCA. Improvements in antigen-capture methods have resulted in better assay 
performance. In addition, several other types of solid-phase antigen-specific assays may be used 
to detect PR3-ANCA and MPO-ANCA162. 
 Indirect immunofluorescence involves incubating diluted patient serum samples with 
ethanol-fixed, permeabilized neutrophils (sometimes pre-attached to glass slides) from healthy 
donors. Bound ANCAs are detected using a fluorescent secondary anti-human IgG antibody, and 
the presence, titre and pattern of fluorescence are assessed by fluorescence microscopy. The two 
patterns of fluorescence that are relevant to AAV diagnosis are a cytoplasmic pattern of ANCA 
staining (cANCA) that is strongly associated with PR3-ANCA and a perinuclear pattern 
(pANCA) that in AAV is strongly associated with MPO-ANCA. The pANCA pattern is a 
consequence of ethanol fixation, as the highly cationic MPO localizes around the negatively 
charged neutrophil nucleus after ethanol fixation. 
 Approaches to ANCA testing when AAV is suspected are informed by consensus 
statements, although substantial variation exists in practice267. With improved immunoassay 
performance, the approach recommended by an international consensus statement162 after a large 
multicentre study268 is to use antigen-specific assays for PR3-ANCA and MPO-ANCA as the 
initial screening method when AAV is suspected, with IIF only performed if these assays are 
negative. Approaches based on 1999 guidelines269, which are still used in some diagnostic 
laboratories, involve a combination of IIF screening with specific PR3-ANCA and MPO-ANCA 
ELISAs for positive samples, or using both methods for each sample. 
 Although ANCAs are primarily associated with AAVs, a positive ANCA test by IIF 
occurs in other diseases, including infections, such as tuberculosis, Pseudomonas aeruginosa 
infection in individuals with cystic fibrosis270,271 and infective endocarditis (PR3-ANCA or 
MPO-ANCA can occur272-274), an important differential diagnosis as unwarranted 
immunosuppression has life-threatening consequences. An atypical ANCA (aANCA pattern) 
resembling (but differing from) pANCA can occur in gastrointestinal tract diseases270, including 
ulcerative colitis, and some liver diseases.,ANCAs can also occur in other autoimmune diseases, 




of AAV or AAV-like features in a minority of people with these diseases). Drug-associated 
AAV is associated not only with MPO-ANCA but also anti-lactoferrin and anti-neutrophil 
elastase antibodies. 
Other proteins associated with a positive IIF ANCA test include azurocidin, 
bactericidal/permeability increasing protein and cathepsin G. Their clinical utility is unproven 





Box 2. Clinical features of the ANCA-associated vasculitides  
Granulomatosis with polyangiitis (GPA) 
 Symptoms of systemic vasculitis, such as fever, weight loss, malaise and fatigue. 
Symptoms and signs of small vessel vasculitis, often in the ear, nose and throat (ENT) tract 
(nasal and oral ulcers and crusting, nose bleeds, nasal polyps, paranasal sinusitis, cartilaginous 
destructions with granulomas on biopsy, hearing impairment and otorrhea), the eyes 
(conjunctival injection, eye pain, diplopia, proptosis, uveitis and retroorbital mass), the airways 
and lungs (hoarseness, cough, dyspnoea, stridor, pleuritic pain, pulmonary nodules, infiltrates, 
cavities and haemorrhage with granulomatous inflammation on biopsy), the kidneys (urinary 
abnormalities, elevated serum creatinine with variable degrees of proteinuria and rapidly-
progressing pauci-immune glomerulonephritis on biopsy), the peripheral nervous system 
(mononeuritis) and the skin (purpura, focal necrosis, ulcers and leukocytoclastic vasculitis on 
biopsy). 
 
Microscopic polyangiitis (MPA) 
 Symptoms of systemic vasculitis, such as fever, weight loss, malaise, and fatigue. 
Symptoms and signs of small vessel vasculitis are as for GPA, but without granulomatous 
inflammation on biopsy. ENT tract manifestations are as in GPA but less frequent. The kidneys 
(rapidly progressing necrotizing pauci-immune glomerulonephritis) and the skin (necrotizing 
leukocytoclastic vasculitis) are commonly affected. 
 
Eosinophilic GPA (EGPA) 
 Many but not all individuals with EGPA have clear features of vasculitis. Symptoms of 
systemic vasculitis include fever, weight loss, malaise, fatigue and lymphadenopathy. Small 
vessel vasculitis of skin, peripheral nervous system, kidneys, heart, and gastrointestinal tract 
occurs. Cardiac involvement, including cardiomyopathy, contributes considerably to mortality in 
EGPA. Asthma is a near universal feature of EGPA and usually precedes vasculitis. Pulmonary 
infiltrates and >10% eosinophilia in peripheral blood are common. ENT involvement is frequent, 





Box 3: Drug-induced vasculitis 
Various drugs are associated with ANCA+ vasculitis, with at least some features of AAV. 
Propylthiouracil (PTU) and, to a lesser extent, some other antithyroid drugs are fairly commonly 
associated with MPO-ANCA, with some people developing an MPA-like vasculitis275. Other 
drugs, including hydralazine (an anti-hypertensive vasodilator), minocycline (a tetracycline 
antibiotic) and cocaine adulterated with the antihelminthic agent levamisole are associated with 
ANCA+ vasculitis276. Leukotriene antagonists have been implicated in EGPA, although causality 
is unclear277. The therapeutic agents associated with ANCA+ vasculitis have been listed in detail 
elsewhere275. The epidemiology of drug-induced vasculitis largely reflects the patterns of use of 
these drugs in different populations (for example, PTU is widely used in China, whereas 
cocaine–levamisole is more common in the USA). 
Clinically, a pANCA pattern is most common, but concurrent pANCA and cANCA 
positivity is common in cocaine–levamisole-induced vasculitis. Autoantibody specificities 
include MPO-ANCA and other, non-classical ANCA antigens (Box 1)275,276. Patients are often 
younger. Clinical manifestations can mimic AAV but are often less severe. Skin involvement 
may be more prominent, variant in nature and severe, particularly with cocaine–levamisole, and 
neutropenia can be present in vasculitis secondary to PTU or cocaine–levamisole. Anti-nuclear 
antibodies may be present, and hydralazine and minocycline are both associated with a lupus-
like phenotype. 
The mechanisms that underpin drug-induced vasculitis are unclear, although some clues 
exist. Levamisole and minocycline have immunomodulatory effects. PTU inhibits thyroid 
peroxidase, which shares sequence homology with MPO, and alters the structure and function of 
MPO in rats275,278. Furthermore, PTU induces abnormal NET formation in vitro and MPO-AAV 
in vivo in rats279. These data, as well as cocaine–levamisole’s effects on NET formation280 
support aberrant autoantigen exposure in the development of drug-induced AAV. 
Recognition of drug-induced vasculitis using an appropriate index of clinical suspicion, 
obtaining a medication history and enquiring as to illicit drug use, potentially with urinary 
screening, is central to the management of these conditions. Ceasing the potential offending 
agent often results in improvement. However, immunosuppression may be required and severe, 
organ-threatening disease can occur. Re-challenge with the suspected drug for diagnostic 





Box 4. A patient’s experience of AAV  
Being diagnosed with a rare and potentially life-threatening disease is something that no one 
expects to happen to them. Many patients with AAV have substantial delays in time to diagnosis 
and may have had serious hospitalizations and organ damage by the time they are diagnosed. 
But once the initial crisis is over, the ongoing work to achieve and maintain remission begins. It 
is important to note that AAV is typically a life-long chronic condition that will require constant 
vigilance by patients and their doctors. Fortunately, there have been new treatment options for 
AAV in recent years, especially new biologic therapies. However, these medications have little 
or no impact on the fatigue and pain caused by AAV. Thus, while patients may be ‘in remission’ 
with the help of ongoing immunosuppressive therapy, many of us still feel the relentless effects 
of this fatigue and pain on a daily basis. Patients also worry about the potential adverse effects 
from the treatments and the balancing of toxicity from the treatment against damage from the 
vasculitis itself. Better treatments for AAV are needed, especially less toxic substitutes for 
glucocorticoids. But also needed are better ways to measure disease activity, such as biomarkers 
that will distinguish our flares from symptoms caused by other things, such as treatment toxicity 
or infections. In addition, urgently needed are treatment options for symptoms that have a major 
impact on our quality of life, such as fatigue and pain, which often remain unaddressed. Greater 
patient input on setting treatment priorities will help focus attention on our unmet quality of life 
needs. 
 
Jennifer Gordon, PhD. Dr. Gordon has EGPA and serves on the Vasculitis Foundation Vasculitis 
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